Viral vector-based vaccine; DNA-based vaccine; RNA based vaccineCOVID-19 vaccine development protocol:
- A landscape for vaccine technology against infectious disease, COVID-19 and tumor.
PSV Based Neutralization Assay
- 1. Landscape of vaccines
- 2. Viral vector-based vaccines
- 1) AAV vector-based vaccines
- 2) Adenoviral vector-based vaccines
- 3) Lentiviral vector-based vaccines
- 4) Comparison of commonly used viral vector-based vaccines
- 3. DNA based vaccines
- 4. RNA based vaccines
- 5. Vaccines development for COVID-19/SARS-CoV-2
- 6. Tumor/Cancer vaccines
- 7. Summary
- 8. Reference
The vaccine helps to provoke the immune system and is an efficacious means for disease prevention and treatment. At this particular time of the COVID-19 outbreak, the vaccine for COVID-19 is urgently needed to save tens of thousands of people’s lives. Here we give some basic information on vaccine classification, generation, and application, and make a brief review on the current status of COVID-19 vaccine and tumor vaccine development both in the clinical trial stage and pre-clinical stage.
1. Landscape of vaccines
A vaccine is any substance produced from various pathogenic microorganisms and can spur the body’s immune system to generate antibodies for the prevention, diagnosis, or treatment of diseases when given to the body, including artificial active immunity vaccine, artificial passive immunity vaccine and novel vaccine (Fig. 1). Traditionally, the artificial active immunity vaccines can be divided into three categories: dead vaccines, live vaccines, and toxoid (Fig. 1). Dead vaccines are dead parts or wholes of germ cells, once injected into people or animals, they can trigger mild immune responses, containing pertussis vaccine, typhoid vaccine, meningococcal vaccine, cholera vaccine, etc.; while live vaccines are living parts or all of germ cells, most of them are attenuated to reduce the risk but also provide immunity for the body, such as BCG vaccine, polio vaccine, measles vaccine, plague vaccine, etc.; toxoid is a kind of extracellular toxin treated by formaldehyde, which loses the toxicity but retains the immunogenicity, such as diphtheria toxoid, tetanus toxoid. Considering the long-term required for immune system activation using artificial active immunity, the artificial passive immunity vaccine is designed for rapid disease treatment or emergency prevention, including antitoxin, immunoglobin, cytokine, and monoclonal antibodies.
Besides these two kinds of immunity vaccines, some novel vaccines have been developed or created, such as subunit vaccine, conjugate vaccine, synthetic peptide vaccine, and genetic engineering vaccine (recombinant protein-based vaccines, lipid-based vaccines, polysaccharides-based vaccines, viral vector-based vaccines, and mRNA/DNA vaccines, etc.). However, some of them, such as lipid-based vaccines and polysaccharides-based vaccines, only result in poor immunogenicity. The reasons might be that some antigen structures with adjuvant activity are discarded during vaccine preparation, or some vaccines can only trigger one kind of immune responses, such as cell-mediated or humoral immune responses. Among them, viral vector-based vaccines, and mRNA/DNA vaccines can provoke both humoral and cell-mediated immune responses, which are promising candidates with great potential in the future.
2. Viral vector-based vaccines
Viral vector-based vaccines are vaccines that can deliver specific antigen gene to target cells based on the infection ability of viruses, produce antigens via the nutrition substances in host cells, and then provoke immune responses with the newly synthesized antigens. Compared with the traditional vaccines, viral vector vaccines have a great number of advantages: ①highly efficient in gene transduction; ② mediate specific gene delivery to target cells; ③induce of both humoral and cell-mediated immune responses; ④ better efficacy and safety;⑤ just need low administration dose; ⑥ easy to be applied into large-scale manufacturing; ⑦ possessing widespread potential target diseases, ranging from infectious diseases to cancers. As well, some drawbacks also have been discovered: ① several kinds of vectors mediate gene integration into host genome, which may lead to cancer; ② some hosts may be exposed to antigens prior to the vaccine administration, which may result in the production of neutralizing antibodies (pre-existing immunity) and thus reduce the vaccine efficacy .
To date, numerous kinds of viral vectors have been introduced to produce vaccines, such as adeno-associated virus (AAV) vectors (Fig. 2A), adenoviral vectors (Fig. 2B) and lentiviral vectors (Fig. 2C) . Different kinds of viral vectors have their advantages and drawbacks, which are summarized in Table 1.
Figure 2. Schematics of viral structure and antigens that may stimulate host immune system . (A) AAV viral vector-based vaccines. (B) Adenoviral vector-based vaccines. (C) Lentiviral vector-based vaccines. dsDNA: double-stranded DNA; TLR: toll-like receptor; cGAS: cyclic GMP-AMP synthase; IFN: interferon; APCs: antigen presenting cells; CTL: cytotoxic T lymphocyte; dsRNA: double-stranded RNA; MDA5: melanoma differentiation-associated protein 5; pDC: plasmacytoid dendritic cell; ssRNA: single-stranded RNA.
|Genome||ss RNA||ds DNA||ss DNA|
|Time to peak expression||72h||36h-72h||Cell: 7 days;
Animals: 2 weeks
|Sustainable time||Stable expression||Transient expression||> 6 months|
|Cell Type||Most Dividing/Non-Dividing Cells||Most Dividing/Non-Dividing Cells||Most Dividing/Non-Dividing Cells|
|Titer||10^8 TU/ml||10^11 PFU/ml||10^12 vg/ml|
|Animal experiment||Low efficiency||Lowest efficiency||Most suitable|
1) AAV vector-based vaccines
Adeno-associated virus (AAV) is a small single strand DNA virus, member of human parvovirus [3, 4], approximately 25nm in diameter and encapsidates a single-stranded DNA genome of 4.7 kilobases (Fig. 3A). The genome consists of two large open reading frames (ORFs) flanked by 145bp inverted terminal repeats (ITR), which are the only cis-acting elements required for AAV genome replication and AAV packaging. The left ORF encodes four replication proteins, Rep40, Rep52, Rep68, and Rep78, in charge of site-specific integration, as well as regulation of AAV capsid formation initiation within the AAV genome, while the right ORF encodes the viral structural proteins, VP1, VP2, and VP3, which interact together to assemble into icosahedral virion shells comprising 60 subunits each (Fig. 3B).
Figure 3. AAV genome map. (A) The capsid structure of AAV. (B) The positions of the three promoters (p5, p19, p40) as well as the seven protein coding regions of the AAV have been highlighted.
Principle of AAV entry into cells
AAV transduces cells through several stages: ① viral binding to cell surface receptor/coreceptor, ② endocytosis of the virus, ③ intracellular trafficking of the virus through the endosomal compartment, ④ endosomal escape of the virus, ⑤ intracellular trafficking of the virus to the nucleus and nuclear import, ⑥ virion uncoating, ⑦ viral genome conversion from a single-stranded to a double-stranded genome capable of expressing an encoded gene [5-7]. Since AAV has no ability to encode polymerases, AAV is dependent upon cellular polymerase activity to replicate its own genome . The presence of a helper virus such as adenovirus is indispensable for wild-type AAV to facilitate gene expression and replication (Fig. 4A). Without helper virus, expression of Rep68/Rep78 would be restricted owing to Ying Yang 1 (YY1) repression of the P5 promoter, leading to inhibition of AAV genome replication and gene expression, and initiation of AAV chromosome integration (Fig. 4B) . AAV establishes latency by undergoing specifically integration into a genome site, termed as the adeno-associated virus integration site 1 (AAVS1), a 4kb region on chromosome 19 (q13.4).
Figure 4. AAV life cycle. (A) AAV can amplify itself with the help of helper virus. (B) AAV establishes latency by undergoing specifically integration into AAVS1 without helper virus.
Immune responses induced by AAV-based vaccine
During the entry of AAV into host cells, AAV virions may uncoat and release their genomes into the endosome, and be recognized by toll like receptor 9 (TLR9) of plasmacytoid dendritic cell (pDC) to provoke innate immune response and produce Interferon (IFN) α/β . This process is dependent on MyD88 signaling, but not the form of transgene or capsid serotype . Besides TLR9, TLR2 dependent cytokine expression was also observed in Kupffer cells . Moreover, some AAV virions are degraded and processed into peptides within proteasomes, and then presented by MHC I of antigen presenting cells (APCs), such as conventional dendritic cells (cDCs), which can be targeted by capsid-specific CD8+ T cells to lyse virally infected cells . In addition to IFNα/β, CD40-CD40L co-stimulation by CD4+ T helper cells, is required for cross-priming of CD8+ T cells against AAV capsid . CD4+ T helper cells is also indispensable to generate memory responses and stimulate B cells to produce antibody against AAV capsid, which is dependent on MyD88 signaling .
Figure 5. Schematic principle of AAV-induced immune responses . IFNAR-1: interferon alpha/beta receptor 1; cDC: conventional dendritic cell; pDC: plasmacytoid dendritic cell; IFN: interferon; TLR: toll-like receptor; MyD88: myeloid differentiation primary response protein (88); MHC: major histocompatibility complex; moDC: monocyte-derived dendritic cell; CD: cluster of differentiation.
Over the past decades, numerous AAV serotypes have been identified with variable tropism. To date, 12 AAV serotypes and over 100 AAV variants have been isolated from adenovirus stocks or from human/nonhuman primate tissues. Among them, AAV2, AAV3, AAV5, AAV6 were discovered in human cells, while AAV1, AAV4, AAV7, AAV8, AAV9, AAV10 (AAVrh10), AAV11, AAV12 in nonhuman primate samples . Different serotypes have different tissue tropism, which are summarized in Table 2.
|AAV Serotype||Tissue tropism|
Though wild-type AAV is not associated with human disease, it is naturally defective and requiring helper adenovirus or herpes simplex virus (HSV) coinfection for AAV replication, so recombinant AAV (rAAV) has been developed for gene therapy or vaccines by replacing the viral genome with gene of interest (GOI) to reduce the risk. Traditionally, rAAV vectors used in clinical trials were prepared with a plasmid containing the therapeutic gene flanked by AAV-inverted terminal repeats (ITRs), co-transfected with AAV packaging plasmid pAAV-RC (AAV replication and AAV capsid) and pHelper (AAV helper plasmid) (Fig. 6). The adenovirus helper factors, such as E1A, E1B, E2A, E4 ORF6 and VA RNAs, would be provided by the third helper plasmid. Due to the deletion of Rep and Cap coding regions between the ITRs, rAAV vectors cannot integrate into the genome of host cells, just persist in an episomal form, which significantly reduced their tumorigenicity.
Figure 6. The three plasmids co-transfection system of recombinant AAV. pAAV-GOI: an AAV ITR-containing plasmid carrying the gene of interest (GOI); pAAV-RC: an AAV serotype plasmid that carries Rep and Capsid genes; pHelper: an AAV helper plasmid that provides the helper genes isolated from adenovirus.
AAV-based gene therapy
To date, more than 244 clinical trials have been carried out using AAV vectors for gene delivery , and promising gene therapy outcomes have been achieved from Phase 1, Phase 2 and Phase 3 trials for a great number of diseases, including lipoprotein lipase deficiency (LPLD) , spinal muscular atrophy (SMA) , retinal dystrophy [20, 21], cystic fibrosis [22, 23], Duchenne Muscular Dystrophy , Hemophilia , congestive heart failure , Parkinson's disease  and Rheumatoid Arthritis [28, 29].
AAV-based vaccine development
But, as a viral vector used for vaccine production, AAV only induces mild immune responses, which is not enough for vaccine to provoke the immune system in host. Several animal studies show that AAV vector-based vaccines can be used to defense HIV-1 [30-32], influenza , and papillomavirus  and have great potentials in clinical applications. However, AAV vector-based vaccines are rarely applied in clinical trials. Some of the examples are listed in the following Table 3. There are two reasons: ① AAV vectors only cause mild humoral and cellular immunity; ② infectious vaccines transduce a large population of people ranging from children and adolescents, and more safety risks need to be considered. Therefore, compared to the gene therapy with AAV vectors, there is a long way for the clinical applications of AAV vector-based vaccines.
|Disease||Vaccine component||Status||Clinical trials|
|Stage IV gastric cancer||AAV-DC-CTL||Phase I||NCT01637805|
|Stage IV gastric cancer||AAV-DC-CTL||Phase I||NCT02496273|
Advantages and disadvantage
AAV viral vector has been developed into a very attractive candidate for gene delivery due to various advantages: ① superior biosafety rating of recombinant AAV after removing most AAV genome elements; ② stable physical properties; ③ broad range of infectivity, AAV has the ability to infect both dividing and quiescent cells in vivo; ④ mediate long term and stable gene expression.
However, there are also some drawbacks for AAV to be used as vaccine vector: ① limited cloning capacity (less than 4.7kb) of the vector, which restricts its use in gene delivery of large genes ; ② only inducing mild immunity, restraining the vaccine development; ③ pre-existing immunity and neutralizing antibodies (NAB) against AAV vectors may attenuate the effect of AAV-based gene therapy or vaccines .
To improve the efficacy of AAV vector for vaccine development, several strategies are adopted: ① assemble and recombine proteins between different viruses, which can produce hybrid rAAVs, such as transcapsidation, which is a process involving the packaging of the ITR from one AAV serotype into the capsid of another serotype, which may determine the tissue tropism of hybrids. ② Recombine, redesign, or introduce random mutations into the capsid protein of AAV by different methods to artificially increase the variance of AAV serotypes, and then screen the appropriate AAV serotypes, including rational design AAV capsid , AAV directed evolution , point mutation , peptide display , and DNA shuffling . ③ In combination with other kinds of vaccines.
GeneMedi holds the expertise at AAV production, you can find more information and protocols about AAV on this website: https://www.genemedi.net/i/aav-packaging.
1) Adenovirus (AdV) vector-based vaccines
Adenovirus (AdV) is a member of the family Adenoviridae, whose name derives from their initial isolation from human adenoids in 1953 . It is a medium sized (90-100nm) and non-enveloped virus with an icosahedral nucleocapsid containing a 36kb double stranded DNA genome (Fig. 7A). Hexon and penton structures form the capsid of AdV, and fiber protein mediates the binding of the virion to the cell surface and is a major determinant of viral tropism. Adenovirus transcription is a two-phase event, early and late, occurring before and after viral DNA replication, respectively (Figure. 7B). The early transcribed regions are E1A, E1B, E2A, E2B, E3, and E4, involved in viral transcription regulation, viral DNA replication, and the suppression of host immune response during infection. The late transcribed genes are L1-L5, encoding viral capsid components (Fig. 7B).
Figure 7. Schematic of the adenovirus genome and adenovirus-based vectors. (A) Capsid crystal structure. (B) Adenovirus gene map. Top panel: a simplified map of the adenovirus serotype 5 genome showing the early genes (E1–E4) and the region from which the major late transcript is produced. Middle panel: general structure of an early region 1 (E1)-deleted Ad vector. Bottom panel: general structure of a helper-dependent Ad vector .
Principle of AdV entry into cells
For most serotypes, adenovirus infection is mediated by the high-affinity binding of the fiber-knob region to a receptor of target cell, named as the coxsackie-Ad receptor (CAR), which mainly determines the viral tropism . Upon attachment, interaction between the penton-base Arg-Gly-Asp (RGD) and cellular αv integrins, which can stimulate actin polymerization, leads to internalisation of the virus into the endosome. Then the endosome acidifies, resulting in disassociation of capsid proteins and transportation of viral DNA into nucleus. Without integration into host genome, adenovirus genome remains in an episomal state, which guarantees the low risk of mutation (Fig. 8). Life cycle of adenovirus is separated by DNA replication process into two distinct phases: the early and late, occurring before and after viral DNA replication, respectively. After the synthesis of viral genome and capsid, they are assembled into viral products, releasing out of cell, and the infected cell starts lysis . To prevent infected cell lysis, recombinant replication deficiency virus has been developed as a gene delivery tool to replace wild-type adenovirus (recombinant AdV in “application” part). Once packaged into a E1-complementing cell line, which provides the E1 products in trans, such as QBI 293A Cells, recombinant viral will be easily propagated.
Figure 8. Infection process of adenovirus. CAR receptor-fiber-knob adenovirus interaction and internalization process .
Immune responses induced by AdV
The entry of AdV into human body stimulates a wide spectrum of innate cellular responses, which might last a few minutes to hours and result in blood pressure changes, thrombocytopenia, inflammation, and fever . AdV vector in blood activates vascular endothelial cells to release von Willebrand factor (vWF), induces platelets to expose the adhesion molecule P-selectin, and promotes the formation of platelet-leukocyte, ultimately leading to thrombocytopenia and bleeding . Additionally, the hexon component of AdV capsid can bind to coagulation factor X (FX) to activate TLR4 on the surface of splenic macrophages and thereby stimulate NF-κB dependent activation of IL-1β, which may help recruit polymorphonuclear leukocytes to the marginal zone of the spleen and clear virus from the spleen rapidly [49, 50]. Besides binding to coagulation proteins, AdV in blood vessel can also bind to component C3 and natural [51-55]. Antibody-AdV complexes can provoke inflammatory cytokine and chemokine responses in macrophages via the intracellular antibody receptor TRIM21 [56-59].
In addition to innate immune responses in circulation, AdV virions can also be trapped by splenic macrophages (MFs) of the MARCO subset via the binding of fiber knob of the capsid to integrin b3 receptor . This binding process leads to the release of IL-1α and activation of IL-1 receptor, promoting chemokines production and attracting other innate immune cells to kill AdV infected MFs . AdV also activates the NLRP3 inflammasome to recruit proinflammatory caspases and promote IL-1β expression, thereby resulting in necrotic cell death . Cytosolic sensing of AdV DNA via cyclic GMP-AMP synthase (cGAS) binds to stimulator of interferon genes (STING) to promote IRF3 phosphorylation to produce type I IFN [63, 64]. Moreover, AdV DNA is also sensed by the endosomal receptor TLR3, TLR7, and TLR9 to activate MyD88 signaling pathway. Nuclear sensing mechanisms of AdV DNA can also promote or inhibit immunity [65, 66]. These pathways cooperate to regulate the immune responses triggered by AdV vectors.
In the meantime, AdV also provoke highly effective adaptive immune responses, and the mechanism is similar to that of AAV. But contrary to AAV, AdV triggers a particularly strong CD8+ T cell responses, which is facilitated by potent induction of Th1 immunity . Due to the induction of extremely strong immune responses, AdV vectors are a prerequisite vector for vaccine development.
Figure 9. Schematic principle of AdV-induced innate immune responses . dsDNA: double-stranded DNA; NLPR3: NACHT, LRR and PYD domains-containing protein 3; ASC: Adaptor Protein Apoptosis-Associated Speck-Like Protein Containing CARD; Pro-casp 1: pro-caspase 1; IFNAR-1: interferon alpha/beta receptor 1; Jak1: Janus kinase 1; Tyk2: tyrosine kinase 2; Stat: signal transducer and activator of transcription; P: phosphoryl group; MDA5: melanoma differentiation-associated protein 5; dsRNA: double-stranded RNA; RIG-I: retinoic acid-inducible gene-I; MAVS: mitochondrial antiviral signaling protein; STING: stimulator of interferon genes; IRF: interferon response factor; cGAS: Cyclic GMP-AMP Synthase; TLR: toll-like receptor; ISG: interferon-stimulated genes; IFN: interferon; MyD88: myeloid differentiation primary response protein (88); NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells; ssRNA: single-stranded RNA.
Since wild-type adenovirus is associated with a wide range of illnesses and enlists a variety of immune responses, so recombinant replication deficiency virus has been an attractive vector for gene therapy . To date, there have been many different generations of adenovirus vectors, differing in the extent to which the genome from wild-type adenovirus is attenuated. Based on human adenovirus type 5 (Ad5), recombinant adenovirus (Ad) a replication-defective adenoviral vector system, is widely used for gene delivery in most dividing and non-dividing cells based on its advantages in high transduction efficiency, high level of transgene expression, and broad range of viral tropism . Traditionally, recombinant adenovirus vectors used in gene delivery were prepared with a plasmid containing the transgene flanked by inverted terminal repeats (ITRs), co-transfected with packaging plasmid pAd-BHGlox(delta)E1,3 (Fig. 10). Once packaged into a E1-complementing cell line, such as QBI 293A cells, recombinant viral will be easily propagated.
Figure 10. The two plasmids co-transfection system of recombinant adenovirus. pAd-EF1-MCS-CMV-EGFP: an adenovirus ITR-containing plasmid carrying multiple clone sites, which can be cloned into a transgene; pAd-BHGlox(delta)E1,3: a packaging plasmid.
AdV vector-based gene therapy
To date, more than 535 clinical trials have been carried out using adenovirus vectors for gene delivery , and promising gene therapy outcomes from recombinant adenovirus have been achieved from clinical trials for a great number of diseases, especially for cancer treatment, such as prostate cancer , chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) , non-small cell lung cancer (NSCLC) , melanoma , renal cell carcinoma .
AdV vector-based vaccine development
As a viral vector used for vaccine production, AdV induces strong immune responses and show better superiority than other viral vectors. In clinical trials, AdV vector-based vaccines have been used to prevent HIV-1 [75, 76], influenza , tuberculosis , and solid tumors . Some of examples in clinical trials are listed in Table 4 . However, there are also some reports with discouraging outcomes. For example, Ad5 vector with neutralizing antiserum against HIV contrarily significantly facilitated HIV infection besides the enhanced immune responses . The pre-existing anti-AdV immunity against Ad5 is proved to be another limiting factor for the clinical application of Ad vector-based vaccines . Therefore, although AdV vector exhibits some advantages over AAV vector in vaccine production, there are also some safety hazards and pre-existing anti-AdV immune responses needed for further exploration.
|Infectious diseases||HIV||Phase I/II||
|Hepatitis C virus||Phase I/II||NCT02309086|
|Ebola virus||Phase I/II||NCT02289027|
|Ebola virus||Phase II||NCT02344407|
|Solid tumor/tissue sarcoma||Phase I/II|
Advantages and disadvantage
There are many advantages of AdV as a vector for clinical trials: ① well tolerated with no obvious influences on the cell viability after infection; ② great packaging capacity (up to 8kb); ③ broad range of infectivity, from dividing cells to non-dividing cells; ④ high infection efficiency; ⑤ no integration ability into the host genome, remaining epichromosomal in host cells, thus no oncogenicity; ⑥ inducing a wide variety of immune responses, including humoral and cellular immunity. These advantages make AdV as an excellent vector for vaccine development.
Although adenovirus benefits a great deal of disease prevention, it does present some drawbacks: ① AdV-mediated gene delivery may not sustain for long time, just transient expression; ② pre-existing immunity and neutralizing antibodies (NAB) against AdV vectors might attenuate the preventive effects of AdV vector-based vaccines ; ③ despite reduced overall virulence, recombinant Ad5-based vectors exhibit a strong tropism for liver parenchymal cells due to the high expression level of CAR in hepatocytes, which increases hepatotoxicity and limits the clinical use of AdV vectors .
Several measures were taken to improve the efficacy of AdV vector for vaccine development: ① modify the fiber protein to alter the tissue tropism and decrease the hepatic toxicity ; ② reduce viral vector-derived immune responses by changing virus gene expression, such as deleting E1 and E4 gene of AdV ; ③ modify the fiber protein to enhance the transduction of T cells and dendritic cells .
Genemedi got a rich experience in adenovirus packaging, you could find more information on https://www.genemedi.net/i/adenovirus-packaging.
3) Lentiviral vector-based vaccines
Lentivirus (lente-, Latin for "slow") is a genus of retroviruses, medium sized (80-100nm) and enveloped, slightly pleomorphic, spherical with an isometric nucleocapsid containing two copies of positive-sense ssRNA genome (Fig. 11A). Most lentiviral vectors are based on the Human Immunodeficiency Virus (HIV), which causes AIDS, a chronic and deadly diseases in human or other mammalian species . Its DNA genome, transcribed from HIV-1 ssRNA, is approximately 9.7 kb and contains 9 open reading frames (ORFs), which are flanked by 5’ and 3’ long terminal repeats (LTRs), which are required for HIV-1 life cycle, such as reverse transcription, integration, and gene expression (Fig. 11B).
Figure 11. Schematic of the lentivirus genome and lentivirus-based vectors. (A) Capsid crystal structure. (B) The viral genome encodes structural, regulatory and accessory genes flanked by LTRs . There are 9 ORFs in lentiviral genome: env and gag responsible for structural proteins; pol for reverse transcriptase and integrase; tat and rev for gene regulatory proteins; vif, vpr, vpu, and nef for viral accessory proteins.
Principle of lentivirus entry into cells
HIV-1 virus enters host cells through binding to the CD4 receptor or a coreceptor (CCR5 or CXCR4) with gp120 protein, thereby anchoring itself onto host cell surface, allowing fusion between the cellular and viral membranes. After entry into the cell, the viral nucleoprotein together with the contents, i.e. the genomic ssRNA, is released into cytoplasm. Then, utilizing the cellular nucleotides as the building blocks, double-stranded DNA is generated from the virus genome ssRNA directed by the HIV-1 reverse transcriptase (RT) in a nucleoprotein complex termed the RTC. Together with other viral proteins, the newly synthesized DNA constitutes an integration-competent nucleoprotein complex, migrating into host cell nucleus and mediating integration of viral DNA into host chromatin. Integrated viral DNA, named as provirus, becomes part of host genome and serves as a transcription template for the synthesis of viral mRNA and genomic RNA. Following the synthesis of viral genomes and proteins, the viral components are assembled together to produce new virions, the virus particles then bud out of host cell and undergo a maturation step to generate infectious HIV-1 (Fig. 12) .
Immune responses induced by lentivirus
Compared to HIV-1 virus, lentiviral vectors elicit weaker IFNα responses from pDC. SsRNA molecules of lentiviral vector in endosomes can be sensed by TLR7, while the reverse-transcribed CpG DNA is sensed by TLR9. TLR7 and TLR9 both contribute to induction of T1 IFN [91, 92] and regulation by mTOR pathway . In addition to innate immune responses, lentiviral vector efficiently transduces APCs, such as MFs and DCs, which significantly facilitates the immune responses against transgene antigen. It was reported that transgene antigen expression in pDCs mainly drives immune responses, while antigen expression in myeloid cells may not obviously provoke immune responses [94, 95]. Furthermore, cell-derived MHC I molecules also helps trigger T cellular immune responses.
Recombinant lentiviral vector
Since wild-type HIV-1-based lentivirus is associated with destruction of host immune system, especially CD4+ helper T lymphocytes, multiple generations of lentivirus vectors have been designed with enhanced safety features and as attractive vectors for gene therapy and vaccine production. To date, there have been several generations of HIV-1-based lentivirus vectors by deleting the HIV viral envelope and some of the regulatory genes not required during vector production . The recombinant lentiviral vectors in GeneMedi are prepared based on three plasmids co-transfection system: vector plasmid pLV-CMV-MCS-T2A-PURO, envelope expressing plasmid pMD2G, and packaging plasmid pSPAX2 (Fig. 14). Once packaged into 293T, recombinant lentiviral vectors will be easily produced.
Figure 14. The three plasmids co-transfection system of recombinant lentivirus. pLV-CMV-MCS-T2A-PURO: a lentivirus LTR-containing plasmid carrying multiple clone sites, which can be cloned into a transgene; pMD2G: envelope VSVG expressing plasmid; pSPAX2: packaging plasmid, containing sequences of gag, pol, tat, and rev.
Lentiviral vector-based gene therapy
To date, more than 236 clinical trials have been carried out using lentivirus vectors for gene delivery . For instance, lentiviral vector-based gene delivery into CD34+ HSCs has been used as an alternative in clinical trials and proved to be effective in treatment of several diseases , including β-thalassemia , X-linked adrenoleukodystrophy (ALD) , metachromatic leukodystrophy [99, 100], and Wiskott-Aldrich Syndrome .
Lentiviral vector-based vaccine development
In addition, as a viral vector used for vaccine production, lentiviral vectors can transduce antigen-presenting cells with high efficiency, such as dendritic cells , which provides some priority to lentiviral vector-based vaccines. Animal studies demonstrate that lentiviral vector-based vaccines can provoke both CD8+ T-cells and CD4+ T-cell responses and show great defense effects against melanoma by targeting NY-ESO-1 antigen [102, 103], or Melan-A/MART-1 antigen . Besides, lentiviral vector-based HIV vaccines induce Gag-specific T-cell responses [105-107]. Some examples of LV vector-based vaccines are listed in the following Table 5. Although promising outcomes by lentiviral vector-based have been achieved in animal studies, the virulence of lentivirus still raises safety concerns. As the virulence of immunodeficiency virus is species-specific, feline immunodeficiency virus (FIV)-based vectors have been developed  to combat HIV-1 and the Herpes simplex virus (HSV) with great potential [109, 110].
|Disease||Vaccine component||Status||Clinical trials|
|Leukemia||LV-mediated genetically engineered AML cells||Phase I||NCT00718250|
|ALL||LV-mediated IL-12 expression in AML cells||Phase I||NCT02483312|
|CD19+ B cell Leukemia and Lymphoma||ARTEMIS™||Early Phase 1||NCT03895944|
Advantages and disadvantages
Recombinant lentiviral vectors have a lot of advantages for vaccine development: ① mediating long-term and stable exogenous gene expression by integrating into the host genome; ② great packaging capacity; ③ highly efficient in transfection in both diving cells to non-dividing cells; ④ low pre-existing immunity. However, lentiviral-mediated gene integration into host genome, which might arouse the risk of tumorigenesis. Additionally, the virulence of lentiviral-derived backbone, i.e. HIV-1, also arouses serious safety concern.
To avoid the virulence of HIV-1, FIV-based viral vectors  were discovered and showed great potential for the prevention of HIV-1 and HSV [109, 110]. Moreover, integration-deficient LV vectors are being exploited for vaccine development [111, 112].
4) Comparison of commonly used viral vector-based vaccines
Viral vector-based vaccines can provoke innate and adaptative immune responses in host system besides the transgene antigens, which makes them preferred during vaccine design and development. Nevertheless, the immune responses induced by different viral vectors may have some differences (Table 6). In brief, lentiviral vectors efficiently transduce antigen-presenting cells, but mediate exogenous gene integration into host genome, showing promising prospects as vaccine vectors, especially for the prevention of hematopoietic diseases. Adenoviral vectors induce high immune responses but have pre-existing immunity, exhibiting great promise in vaccine generation and gene therapy against cancers. Whereas, AAV vectors, just inducing mild immune responses and having a large number of serotypes, are the most excellent gene therapy vector but not very suitable to be vaccine vectors (Table 7).
|Viral vector||Lentiviral vector||Adenoviral vector||AAV vector|
|Virion and genome|
Enveloped virus containing capsid and
~10-kb ssRNA genome
|Capsid; 36-kb dsDNA genome|
Capsid, 5-kb ssDNA genome
(or ~2.5-kb scDNA genome)
|Innate immunity||Strong IFNα/β response limits transduction|
and drives adaptive responses
|Potent innate response, including activation of vascular endothelial cells and platelets, inflammatory cytokine production, and macrophage cell death|
Comparatively weak and transient innate response; TLR9 signaling promotes CD8+ T cell responses; complement activation and other immunotoxicities seen in some patients receiving high-dose systemic gene transfer
|Immunity in human population||Low pre-existing immunity||Pre-existing immunity to human serotypes|
Pre-existing immunity varies
between serotypes and geographic location
In vivo transduction of antigen presenting cells
|Use as vaccine carrier|
Targeting of dendritic cells for vaccine development
|Vaccine and cancer gene therapy applications||Limited|
|Adaptive immune responses to vector||NAB formation;|
possibly T cell responses to envelope protein
CD8+ T cell responses to viral gene products (except for high-capacity vectors)
CD8+ T cell responses to capsid
|Adaptive immune responses to transgene products||Efficient inducer of B and T cell responses unless transgene expression is tightly controlled by miRNA and promoter and expression is professional APCs is eliminated||Efficient inducer of CD8+ T cell responses; antibody formation possible|
Least efficient inducer of CD8+ T cells compared to Ad and LV; risk of CD8+ T cell and antibody responses highly variable depending on vector design and dose, route of administration, and host factors
|Vector vaccines||Lentiviral vector-based vaccines||Adenoviral vector-based vaccines||AAV vector-based vaccines|
|Advantages|| ① mediating long-term and stable exogenous gene expression by integrating into the host genome;
② great packaging capacity;
③ highly efficient in transfection in both diving cells to non-dividing cells;
④ low pre-existing immunity
① well tolerated with no obvious influences on the cell viability after infection;
② great packaging capacity (up to 8kb);
③ broad range of infectivity;
④ high infection efficiency;
⑤ no integration ability into the host genome;
⑥ inducing a wide variety of immune responses.
| ① superior biosafety rating;|
② stable physical properties;
③ broad range of infectivity;
④ mediate long term and stable antigen gene expression.
① some risk of tumorigenesis;
② the virulence of vector backbone may raise some safety concern
① inducing transient expression of antigen;
② pre-existing immunity and neutralizing antibodies (NAB);
③ recombinant Ad5-based vectors may have hepatotoxicity
① limited cloning capacity ;
② only inducing mild immunity;
③ pre-existing immunity and neutralizing antibodies (NAB)
|Suitable for vaccine||Suitable||Most suitable||Not suitable|
GeneMedi provides professional services on viral packaging, you could find more information on the following website: https://www.genemedi.net/.
3. DNA based vaccines
Traditionally, vaccines are prepared with killed or attenuated viruses or bacteria, which might have serious security issues for the development of HIV vaccines. Additionally, vector-based vaccines may induce anti-vector immunity, which might interfere the immune responses provoked by vaccines . Thus, DNA vaccines were first created in 1990 with finding that delivery of recombinant plasmid may allow the expression of exogenous antigen protein . Then, the immune responses  and protection against lethal influenza by exogenous plasmid DNA were also discovered [116, 117]. Following these studies, DNA vaccines are demonstrated to be effective for the various diseases, such as infectious diseases, cancers, autoimmune diseases, and allergic diseases.
Generally, the optimized antigen DNA and molecular adjuvant are cloned into plasmid backbone, named as recombinant plasmid. After amplification and purification of the recombinant plasmids, they are delivered into host cells. Utilizing the nutrients and materials of host cells, antigens are transcribed, expressed, and assembled. On the one hand, antigen peptides are recognized and presented on major histocompatibility complex (MHC) class I, while secreted antigen proteins are captured and processed by antigen-presenting cells (APCs) and then presented by MHC class II (MHC II). APCs carrying MHC-antigen peptide complex migrate to lymph node to stimulate T cells and mediate cellular immune response. On the other hand, antigen proteins can be recognized and captured by antigen-specific high affinity immunoglobulins on the B cell surface, then provoke humoral immune response, which is assisted by the pre-activated antigen-specific CD4+ T cells (Fig. 15) .
Figure 15. General principles of immune responses induced by DNA vaccines . MHC: major histocompatibility complex.
Compared with the traditional vaccines, the immunogenicity of DNA vaccines is quite weak. To enhance the immunogenicity, several strategies are utilized: ① stronger promoters are adopted for the cloning of recombinant plasmid, such as APC-specific promotors; ② optimize the delivery route, transducing DNA vaccines into antigen-presenting cells (APCs), such as dendritic cells, may significantly promote the cytotoxic responses; ③ optimization of multiple antigen sequences; ④ adjuvants are used to prevent tolerance induction and facilitate the innate immune signals induced by DNA vaccines, including alum, liposome, nanoparticles, cytokines, chemokines and pathogen-recognition receptor (PRR) agonists; ⑤ circumvent potential inhibitory effects of the vector .
Although DNA vaccines have not been applied widespread due to their weak immunogenicity, promising outcomes are achieved based on improvements the priming high-level antigen specific antibody responses. Some of them are listed in the following Table 8 [120, 121].
|HIV||EnV, ReV||Intramuscular||Phase I||Ab, CTL, T proliferative, chemokine release was observed|||
|HIV||gp120, gp160||Intramuscular||Phase I||No Ab response and cellular response were observed|||
|HIV||ChAdV63||Intramuscular||Phase II||No intervention-related serious adverse events|||
38 cytotoxic T cell epitopes and 16 helper T cell epitopes derived from P. falciparum antigens
|Electroporation||Phase I||poorly immunogenic|||
|Anal||HPV-16 E7 fragment||Intramuscular||Phase I||10/12 patients developed antigen-specific immune responses|||
|B-cell lymphoma||Idiotype||Intramuscular||Phase I/II|
1/12 patient developed T-cell response to autologous Id following initial immunization course; 6/12 patients developed anti-Id responses following booster immunization
|Breast carcinoma||HER2||Intramuscular||Phase I|
3/8 individuals had enhanced CD4+ T cell responses; 3/5 patients have enhanced HER2 Ab responses
|Colorectal cancer||CEA fused to T-helper epitope||intradermal||Phase I||Erythema at injection site increased over time|||
|Colorectal cancer||CEA (along with HBV surface antigen)||Intramuscular||Phase I||4/17 patients developed Hsp65-specific IL-10 responses|||
|Melanoma||gp 100 (mouse)||Intramuscular||Phase I|
4/27 patients developed gp100 tetramer+CD8+ cells; 5/27 developed IFNγ+CD8+ responses, one of which was tetramer+
|Melanoma||gp 101 (mouse and human)||Intramuscular||Phase I||6/18 patients developed gp100-specific T cell responses|||
|Melanoma||Tyrosinase (human and mouse)||Intramuscular||Phase I||7/17 patients developed antigen-specific T-cell responses|||
|Melanoma||MART-1||Intramuscular||Phase I||No enhancement in antigen-specific immune responses|||
|Melanoma||MART-1 and tyrosinase T-cell epitopes||Intra-lymph node||Phase I||4/19 patients developed immune responses to MART-1|||
|Melanoma||Epitopes from five melanoma antigens||Intramuscular||Phase I||22/31 patients developed antigen-specific T-cell responses|||
|Melanoma||gp100||PMED||Phase I||No antigen-specific immune responses detected|||
|Melanoma||HLA-B7||DNA-containing liposomes||Phase I||2/22 patients developed enhanced TIL cytotoxicity|||
|Melanoma||Tyrosinase epitopes||Intra-lymph node||Phase I||11/26 patients had antigen-specific T-cell responses|||
|NSCLC||L523S||Intramuscular||Phase I||1/10 patient developed antigen-specific antibody response|||
4. RNA based vaccines
Though DNA vaccines avoid the anti-vector immunity, long term existence in cells might produce excessive antigens, which might provoke overactive immune responses and exhaust T cells . Thus, another kind of nucleic acid-based vaccines, RNA vaccines, were developed by directly delivering mRNA into cells for the prevention and therapy of diseases. Without the need to entry into cell nucleus, RNA vaccines mainly function in cytoplasm, which might have higher efficiency in delivery .
RNA vaccines can be classified into 2 categories: conventional mRNA-based vaccines and self-amplifying mRNA vaccines (SAM, also termed replicons) (Fig. 9) . Upon entry into cells, conventional RNA vaccines directly generate antigens with nutrients and materials of host cells. On the contrary, SAM vaccines generate antigens by several steps (Fig. 16). SAM can self-replicate in host cells, thus they can mediate high expression levels of antigen. Due to no expression of structural proteins, no virion particle can be produced.
Figure 16. Schematic analysis between conventional mRNA-based vaccines and self-amplifying mRNA vaccines . The processes of antigen generation from self-amplifying mRNA vaccines can be divided into four steps: 1) The genomic (+)RNA encodes and generates the nonstructural proteins (nsP1, nsP2, nsP3, nsP4), producing a RNA-dependent RNA-polymerase (RDRP) complex; 2) RDRP utilizes genomic (+)RNA as template to generate genomic (-)RNA; 3)RDRP utilizes genomic (-) RNA as template to produce genomic (+) RNA and subgenomic RNA; 4) Subgenomic RNA is translated into antigen. 5) Conventional mRNA vaccines can be directly translated into antigen.
Besides the common immune responses induced by endogenous antigens, mRNA vaccine can elicit a robust type I IFN response, which facilitates CD8+ T cell cytolytic capacity and promotes eradication of infected cells . However, some adverse effects are also observed. For example, specific single mutations in nsP1 sequence of alphaviruses, such as A533I, induce elevated Type I IFN expression, but decrease the expression level of antigen and vaccine immunity [144, 145]. To improve the efficacy of RNA vaccines, several strategies are applied: ① Modify or optimize the vaccine backbone, such as 5ʹ cap, poly (A) tail, codon optimization; ② Delivery systems (naked mRNA, formulation with liposomes, lipoplexes, polyplexes, particulate carrier-mediated, electroporation, and gene gun  ) and route of administration (such as intradermal  or intratumor administration ); ③ supplementation with small immunomodulatory molecules can also help improve the immune responses provoked by RNA vaccines, such as dexamethasone .
As a novel kind of vaccine, RNA vaccines have many advantages: ① Induction of humoral immune responses and cell immune responses; ② Provoke stronger immunity than DNA vaccines; ③ Avoid the anti-vector immunity; ④ Mediate transient expression of antigen; ⑤ No integration into host genome. To date, numerous mRNA vaccines have been translated into clinical trials, and several of them are listed in the following Table 9 .
|Melanoma||NY-ESO-1, MAGE-A3, tyrosinase and TPTE||Intravenous||Phase I||IFNα and strong antigen-specific T-cell responses were induced|||
|Non-small cell lung carcinoma (NSCLC)||NY-ESO-1, MAGEC1, MAGEC2, BIRC5, TPBG, and MUC1||Intradermal||Phase I||Improved survival|||
|Melanoma||Melan-A, Tyrosinase, gp100, Mage-A1, Mage-A3, and Survivin in 21||Intradermal||Phase II||Vaccines are feasible and safe, and induce immune response|||
|Melanoma||Melan-A, Tyrosinase, gp100, Mage-A1, Mage-A3, and Survivin in 22||Intradermal||Phase I/II||An increase in antitumor humoral immune response was observed in some patient|||
|Renal cell carcinoma (RCC)||Tumor-associated antigens mucin 1(MUC1), carcinoembryonic (CEA), human epidermal growth factor receptor 2 (Her-2/neu), telomerase, survivin, and melanoma-associated antigen 1 (MAGE-A1)||Intradermal||Phase I/II||Induce CD8+ and CD4+ immune Responses|||
|Renal cell carcinoma (RCC)||MUC1, CEA, Her2/neu, telomerase, survivin, MAGE-A1||Intradermal||Phase I/II||A clear correlation was observed between survival and immunological responses to TAAs|||
|Rabies||Rabies virus glycoprotein (CV7201)||Intradermal or intramuscular||Phase I||Boostable functional antibodies against a viral antigen was observed when administered with a needle-free device|||
|Flu||Hemagglutinin (HA) proteins||Intramuscular||Phase I||Protective immunogenicity with acceptable tolerability profiles were induced|||
5. Vaccines development for COVID-19/SARS-CoV-2
Coronavirus Disease 2019 (COVID-19) is a novel viral pneumonia caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). First discovered in Wuhan, a city in Hubei province of China, COVID-19 has already broken out throughout the world and posed a great threat to the public health, especially in Europe and North America now. Additionally, person-to-person transmission of COVID-19 disease is reported to be extremely rapid [158-160]. To date, more than one million cases were infected with COVID-19 and over 55,000 deaths occurred. Therefore, it is really urgent and noteworthy to develop the vaccines specific to COVID-19/SARS-CoV-2.
Belonging to the Betacoronavirus genus family, SARS-CoV-2 is 60～200nm in diameter and encapsidates a large positive-sense, single-stranded RNA virus (26-32kb) with many spikes on the virus capsid (Fig. 17A). The RNA genome of SARS-CoV-2 encodes several accessory proteins and structural proteins, such as nucleocapsid (N) protein, envelope (E) protein, membrane (M) protein, and spike (S) protein (Fig. 10B). Although the detailed mechanism of SARS-CoV-2 infection has not been clearly illuminated, several studies demonstrated that SARS-CoV-2 enters human cells via utilizing spike (S) protein to bind to the angiotensin converting enzyme (ACE2) on the surface of target cell [161, 162].
Figure 17. SARS-CoV-2 capsid structure and genome map. (A) Three-dimensional structure diagram of SARS-CoV-2. (B) Genome organization of SARS-CoV-2 . ORF: open reading frame. E: envelope. M: membrane. N: nucleocapsid. HR1: heptad repeat 1. HR2: heptad repeat 2. SP: signal peptide. NTD: N-terminal domain. RBD: receptor binding domain. S: spike. S1: subunit 1. S2: subunit 2. TM: transmembrane domain. For more information, see: EMA guidance for COVID-19 vaccine
Since the genome sequences of SARS-CoV were discovered and reported (https://www.gisaid.org/CoV2020/), a large number of pharmaceutical enterprises and research organizations are sparing all efforts to the vaccine development. Different companies utilize different targets and antigen epitopes. Some of the advances are listed in the following Table 10 (from WHO), and most of them focus on viral vector-based vaccines (replicating or non-replicating viral vector-based vaccines), recombinant protein (Spike), and nucleic acid-based vaccines. To date, two COVID-19 vaccines have entered Phase I clinical testing to assess the safety and potency of vaccines. One is mRNA-1273, was developed by Moderna Therapeutics, encoding a prefusion-stabilized form of Spike (S) protein  (https://www.nature.com/articles/d41587-020-00005-z). Another vaccine is recombinant protein of SARS-CoV-2 antigen, developed by Chinese Academy of Military Sciences, Institute of Military Medicine. It was predicted that these vaccines can be applied in clinics in a large scale as early as 2021 if they can successfully pass the clinical testing. Although there is a long way for theses vaccines to be applied for prevention and therapy of COVID-19, they indeed bring great hope and light to people all over the world.
|COVID-19 Vaccine developer/manufacturer||Vaccine platform||Type of candidate vaccine||Number of doses||Timing of doses||
Route of Adminis-
|Phase 1||Phase 1/2||Phase 2||Phase 3|
|Wuhan Institute of Biological Products/Sinopharm||Inactivated||Inactivated||2||0,21 days||IM||
|Beijing Institute of Biological Products/Sinopharm||Inactivated||Inactivated||2||0,21 days||IM||
|Bharat Biotech||Inactivated||Whole-Virion Inactivated||2||0, 28 days||IM||
|University of Oxford/AstraZeneca||Non-Replicating Viral Vector||ChAdOx1-S||2||0,28 days||IM||
|CanSino Biological Inc./Beijing Institute of Biotechnology||Non-Replicating Viral Vector||Adenovirus Type 5 Vector||1||IM||ChiCTR2000030906
|Gamaleya Research Institute||Non-Replicating Viral Vector||Adeno-based (rAd26-S+rAd5-S)||2||0,21 days||IM||NCT04436471
|Janssen Pharmaceutical Companies||Non-Replicating Viral Vector||Adenovirus Type 26 vector||1 2||0 0, 56 days||IM||NCT04436276
|Novavax||Protein Subunit||Full length recombinant SARS CoV-2 glycoprotein nanoparticle vaccine adjuvanted with Matrix M||2||0,21 days||IM||NCT04368988
|Anhui Zhifei Longcom Biopharmaceutical/Institute of Microbiology, Chinese Academy of Sciences||Protein Subunit||Adjuvanted recombinant protein (RBD-Dimer) expressed in CHO cells||3||0, 28, 56 days||IM||NCT04445194
|Moderna/NIAID||RNA||LNP-encapsulated mRNA||2||0,28 days||IM||NCT04283461
|BioNTech/Fosun Pharma/Pfizer||RNA||3 LNP-mRNAs||2||0,21 days||IM||NCT04368728
|Medicago Inc.||VLP||Plant-derived VLP adjuvanted with AS03.||2||0, 21 days||IM||NCT04450004
|Inovio Pharmaceuticals/ International Vaccine Institute||DNA||DNA plasmid vaccine with electroporation||2||0, 28 days||ID||NCT04447781
|Beijing Wantai Biological Pharmacy/ Xiamen University||Replicating Viral Vector||Intranasal flu-based-RBD||1||IN|
|West China Hospital, Sichuan University||Protein Subunit||RBD (baculovirus production expressed in Sf9 cells)||2 or 3||0, 28 days and 0,14, 28 days||IM||ChiCTR2000039994
|Curevac||RNA||mRNA||2||0, 28 days||IM||NCT04449276
|Institute of Medical Biology, Chinese Academy of Medical Sciences||Inactivated||Inactivated||2||0, 28 days||IM||NCT04412538
|Research Institute for Biological Safety Problems, Rep of Kazakhstan||Inactivated||Inactivated||2||0, 21 days||IM||NCT04530357
|Shenzhen Kangtai Biological Products Co., Ltd.||Inactivated||Inactivated||2||IM||ChiCTR2000038804
|Osaka University/ AnGes/ Takara Bio||DNA||DNA plasmid vaccine + Adjuvant||2||0, 14 days||IM||NCT04463472
|Cadila Healthcare Limited||DNA||DNA plasmid vaccine||3||0, 28, 56 days||ID||CTRI/2020/07/026352
|Genexine Consortium||DNA||DNA Vaccine (GX-19)||2||0, 28 days||IM||NCT04445389
|Kentucky Bioprocessing, Inc||Protein Subunit||RBD-based||2||0, 21 days||IM||NCT04473690
|Sanofi Pasteur/GSK||Protein Subunit||S protein (baculovirus production)||2||0, 21 days||IM||NCT04537208
|Biological E Ltd||Protein Subunit||Adjuvanted protein subunit (RBD)||2||0, 28 days||IM||CTRI/2020/11/029032
|Israel Institute for Biological Research||Replicating Viral Vector||VSV-S||1||IM||NCT04608305
|SpyBiotech/Serum Institute of India||VLP||RBD-HBsAg VLPs||2||0, 28 days||IM||ACTRN12620000817943
|Providence Health & Services||DNA||electroporated S protein plasmid DNA vaccine with or without the combination of electroporated IL- 12p70 plasmid||2||0, 28 days||ID||NCT04627675
|Codagenix/Serum Institute of India||Live Attenuated Virus||Codon deoptimized live attenuated vaccines||1 or 2||0 or 0,28 days||IN||NCT04619628
|ImmunityBio, Inc. & NantKwest Inc.||Non-Replicating Viral Vector||hAd5 S+N 2nd Generation Human Adenovirus Type 5 Vector (hAd5) Spike (S) + Nucleocapsid (N)||2||0, 21 days||SC||NCT04591717
|ReiThera/LEUKOCARE/Univercells||Non-Replicating Viral Vector||Replication defective Simian Adenovirus (GRAd) encoding S||1||IM||NCT04528641|
|CanSino Biological Inc/Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China||Non-Replicating Viral Vector||Ad5-nCoV||2||0, 28 days||IM/mucosal||NCT04552366|
|Vaxart||Non-Replicating Viral Vector||Ad5 adjuvanted Oral Vaccine platform||2||0, 28 days||Oral||NCT04563702|
|Ludwig-Maximilians - University of Munich||Non-Replicating Viral Vector||MVA-SARS-2-S||2||0, 28 days||IM||NCT04569383|
|City of Hope, USA||Replicating Viral Vector||SARS-CoV-2 S and NP genes inserted into a sMVA vector||2||0, 28 days||IM||NCT04639466|
|Clover Biopharmaceuticals Inc./GSK/Dynavax||Protein Subunit||Native like Trimeric subunit Spike Protein vaccine||2||0, 21 days||IM||NCT04405908|
|Vaxine Pty Ltd/Medytox||Protein Subunit||Recombinant spike protein with Advax™ adjuvant||1||IM||NCT04453852|
|University of Queensland/CSL/Seqirus||Protein Subunit||Molecular clamp stabilized Spike protein with MF59 adjuvant||2||0, 28 days||IM||ACTRN12620000674932p
|Medigen Vaccine Biologics Corporation/NIAID/Dynavax||Protein Subunit||S-2P protein + CpG 1018||2||0, 28 days||IM||NCT04487210|
|Instituto Finlay de Vacunas, Cuba||Protein Subunit||rRBD produced in CHO-cell chemically conjugate to tetanus toxoid||2||0, 28 days||IM||IFV/COR/06|
|Instituto Finlay de Vacunas, Cuba||Protein Subunit||RBD + Adjuvant||2||0, 28 days||IM||IFV/COR/04
|FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo||Protein Subunit||Peptide||2||0, 21 days||IM||NCT04527575|
|University Hospital Tuebingen||Protein Subunit||SARS-CoV-2 HLA-DR peptides||1||SC||NCT04546841|
|COVAXX / United Biomedical Inc. Asia||Protein Subunit||Multitope peptide-based S1-RBD- protein vaccine||2||0, 28 days||IM||NCT04545749|
|Chinese Academy of Military Sciences||Protein Subunit||Subunit expressed in CHO cells||2 or 3||0, 14 days or 0,14, 28 days||IM|
|Merck Sharp & Dohme/IAVI||Replicating Viral Vector||Replication-competent VSV delivering the SARS-CoV-2 Spike||1||IM||NCT04569786|
|Institute Pasteur/Themis/Univ. of Pittsburg CVR/Merck Sharp & Dohme||Replicating Viral Vector||Measles-vector based||1 or 2||0, 28 days||IM||NCT04497298|
|Imperial College London||RNA||LNP-nCoVsaRNA||2||IM||ISRCTN17072692|
|People's Liberation Army (PLA) Academy of Military Sciences/Walvax Biotech.||RNA||mRNA||2||0, 14 or 0, 28 days||IM||ChiCTR2000034112
|Platform||Type of candidate vaccine||Developer||Coronavirus target||
Current stage of clinical evaluation/regulatory status- Coronavirus
|Same platform for non-Coronavirus candidates|
|DNA||DNA plasmids containing S-gene||Biosun Pharmed||SARS-CoV2||Pre-Clinical|
|DNA||DNA plasmid vaccine||Globe Biotech Limited, Bangladesh||SARS-CoV2||Pre-Clinical|
|DNA||Plasmid DNA, nanostructured RBD||National institute of Chemistry, Slovenia||SARS-CoV2||Pre-Clinical|
DNA, engineered vaccine inserts compatible
with multiple delivery systems
|DIOSynVax Ltd / University of Cambridge||
|DNA||DNA vaccine||Ege University||SARS-CoV2||Pre-Clinical|
|DNA||DNA plasmid vaccine RBD&N||Scancell/University of Nottingham/ Nottingham Trent University||SARS-CoV2||Pre-Clinical|
|DNA||DNA plasmid vaccine S,S1,S2,RBD &N||National Research Centre, Egypt||SARS-CoV2||Pre-Clinical|
|DNA||DNA with electroporation||
Karolinska Institute / Cobra Biologics
|DNA||DNA with electroporation||Chula Vaccine Research Center||SARS-CoV2||Pre-Clinical|
|DNA||DNA||Takis/Applied DNA Sciences/Evvivax||SARS-CoV2||Pre-Clinical|
|DNA||Plasmid DNA, Needle-Free Delivery||Immunomic Therapeutics, Inc./EpiVax, Inc./PharmaJet||SARS-CoV2||Pre-Clinical||SARS|
|DNA||DNA vaccine||BioNet Asia||SARS-CoV2||Pre-Clinical|
|DNA||msDNA vaccine||Mediphage Bioceuticals/University of Waterloo||SARS-CoV2||Pre-Clinical|
|DNA||DNA vaccine||Entos Pharmaceuticals||SARS-CoV2||Pre-Clinical|
|Inactivated||Inactivated + Alum||Shifa Pharmed||SARS-CoV2||Pre-Clinical|
|Inactivated||Inactivated||Milad Pharmaceutics Co.||SARS-CoV2||Pre-Clinical||MMR, IPV|
|Inactivated||Inactivated||Zista Kian Azma Co.||SARS-CoV2||Pre-Clinical||MMR, IPV|
|Inactivated||Inactivated||Kocak Farma Ilac ve Kimya San. A.S.||SARS-CoV2||Pre-Clinical|
Egg-based, inactivated, whole chimeric Newcastle Disease Virus (NDV) expressing membrane-anchored pre-fusion-stabilized trimeric SARS-CoV-2 S protein (Hexapro) +
Institute of Vaccines and Medical Biologicals (IVAC; Vietnam) / Dynavax
Egg-based, inactivated, whole chimeric Newcastle Disease Virus (NDV) expressing membrane-anchored pre-fusion-stabilized trimeric SARS-CoV-2 S protein (Hexapro) +
|Government Pharmaceutical Organization (GPO; Thailand) / Dynavax / PATH||SARS-CoV2||Pre-Clinical|
Egg-based, inactivated, whole chimeric Newcastle Disease Virus (NDV) expressing membrane-anchored pre-fusion-stabilized trimeric SARS-CoV-2 S protein (Hexapro) +
|Institute Butantan (Brazil) / Dynavax / PATH||SARS-CoV-2||Pre-clinical|
|Inactivated||Inactivated + alum||KM Biologics||SARS-CoV2||Pre-Clinical||JE, Zika|
|Inactivated||Inactivated whole virus||National Research Centre, Egypt||SARS-CoV2||Pre-Clinical|
|Inactivated||TBD||Osaka University/ BIKEN/ NIBIOHN||SARS-CoV2||Pre-Clinical|
|Inactivated||Inactivated + CpG 1018||Sinovac/Dynavax||SARS-CoV2||Pre-Clinical|
|Inactivated||Inactivated + CpG 1018||Valneva/Dynavax||SARS-CoV2||Pre-Clinical|
|Live Attenuated Virus||Codon deoptimized live attenuated vaccines||
Mehmet Ali Aydinlar University / Acıbadem Labmed Health Services
|Live Attenuated Virus||Codon deoptimized live attenuated vaccines||Indian Immunologicals Ltd/Griffith University||SARS-CoV2||Pre-Clinical|
|Non Replicating Viral Vector||Ad 5 vector for intranasal administration||University of Helsinki & University of Eastern Finland||SARS-CoV2||Pre-Clinical|
|Non Replicating Viral Vector||Adenovirus Type 5 Vector||Globe Biotech Limited, Bangladesh||SARS-CoV2||Pre-Clinical|
|Non-Replicating Viral Vector||Sendai virus vector||ID Pharma||SARS-CoV2||Pre-Clinical|
|Non-Replicating Viral Vector||Adenovirus-based||Ankara University||SARS-CoV2||Pre-Clinical|
|Non-Replicating Viral Vector||Adeno-associated virus vector (AAVCOVID)||Massachusetts Eye and Ear/Massachusetts General Hospital/AveXis||SARS-CoV2||Pre-Clinical|
|Non-Replicating Viral Vector||MVA encoded VLP||GeoVax/BravoVax||SARS-CoV2||Pre-Clinical||LASV, EBOV, MARV, HIV|
|Non-replicating viral vector||MVA-S encoded||DZIF – German Center for Infection Research/IDT Biologika GmbH||SARS-CoV2||Pre-clinical||Many|
|Non-replicating viral vector||MVA-S||IDIBAPS-Hospital Clinic, Spain||SARS-CoV2||Pre-clinical|
|Non-Replicating Viral Vector||Intranasal Ad5 vaccine encoding RBD||Altimmune, Inc.||SARS-CoV2||IND filed||
Influenza (NasoVAX), Anthrax
|Non-Replicating Viral Vector||Adeno5-based||Erciyes University||SARS-CoV2||Pre-Clinical|
|Non-Replicating Viral Vector||Ad5 S (GREVAX™ platform)||Greffex||SARS-CoV2||Pre-Clinical||MERS|
|Non-Replicating Viral Vector||Oral Ad5 S||Stabilitech Biopharma Ltd||SARS-CoV2||Pre-Clinical||Zika, VZV, HSV-2 and Norovirus|
|Non-Replicating Viral Vector||adenovirus-based + HLA-matched peptides||Valo Therapeutics Ltd||Pan-Corona||Pre-Clinical|
|Non-Replicating Viral Vector||Vaxart||SARS-CoV2||Pre-Clinical||InfA, CHIKV, LASV, NORV; EBOV, RVF, HBV, VEE|
|Non-Replicating Viral Vector||MVA expressing structural proteins||Centro Nacional Biotecnología (CNB-CSIC), Spain||SARS-CoV2||Pre-Clinical||Multiple candidates|
|Non-Replicating Viral Vector||
parainfluenza virus 5 (PIV5)-based vaccine
expressing the spike protein
|University of Georgia/University of Iowa||SARS-CoV2||Pre-Clinical||MERS|
|Non-Replicating Viral Vector||
Recombinant deactivated rabies virus
|Bharat Biotech/Thomas Jefferson University||SARS-CoV2||Pre-Clinical||HeV, NiV, EBOV, LASSA, CCHFV, MERS|
|Non-Replicating Viral Vector||Influenza A H1N1 vector||National Research Centre, Egypt||SARS-CoV2||Pre-Clinical|
|Non-Replicating Viral Vector||Newcastle disease virus expressing S||Icahn School of Medicine at Mount Sinai||SARS-CoV2||Pre-Clinical|
|Protein Subunit||Recombinant spike with adjuvant||Iran||SARS-CoV2||Pre-Clinical||Multiple candidates|
|Protein Subunit||Recombinant S protein produced in BEVS||Tampere University||SARS-CoV2||Pre-Clinical|
RBD protein delivered in mannose-
conjugated chitosan nanoparticle
|Ohio State University / Kazakh National Agrarian University||SARS-CoV2||Pre-Clinical|
Recombinant spike protein with Essai O/W
|Kazakh National Agrarian University||SARS-CoV2||Pre-Clinical|
Recombinant spike protein with Essai O/W
Kazakh National Agrarian University, Kazakhstan / National Scientific
Center for Especially Dangerous Infections
|Protein Subunit||Recombinant S protein||Max-Planck-Institute of Colloids and Interfaces||SARS-CoV2||Pre-Clinical|
RBD protein (baculovirus production) + FAR-
Farmacológicos Veterinarios SAC (FARVET SAC) / Universidad Peruana
Cayetano Heredia (UPCH)
|Protein Subunit||Protein Subunit||Research Institute for Biological Safety Problems, Rep of Kazakhstan||SARS-CoV2||Pre-Clinical|
|Protein Subunit||Recombinant S protein||Izmir Biomedicine and Genome Center||SARS-CoV2||Pre-Clinical|
|Protein Subunit||Peptide + novel adjuvant||Bogazici University||SARS-CoV2||Pre-Clinical|
S subunit intranasal liposomal formulation
with GLA/3M052 adjs.
|University of Virginia||SARS-CoV2||Pre-Clinical|
S-Protein (Subunit) + Adjuvant, E coli based
Helix Biogen Consult, Ogbomoso & Trinity Immonoefficient Laboratory,
Ogbomoso, Oyo State, Nigeria.
|Protein Subunit||Protein Subunit S,N,M&S1 protein||National Research Centre, Egypt||SARS-CoV2||Pre-Clinical|
|Protein Subunit||Protein Subunit||University of San Martin and CONICET, Argentina||SARS-CoV2||Pre-Clinical|
|Protein Subunit||RBD protein fused with Fc of IgG + Adj.||Chulalongkorn University/GPO, Thailand||SARS-CoV2||Pre-Clinical|
|Protein Subunit||Capsid-like Particle||AdaptVac (PREVENT-nCoV consortium)||SARS-CoV2||Pre-Clinical|
Drosophila S2 insect cell expression system
|Protein Subunit||Peptide antigens formulated in LNP||IMV Inc||SARS-CoV2||Pre-Clinical|
|Protein Subunit||S protein||WRAIR/USAMRIID||SARS-CoV2||Pre-Clinical|
|Protein Subunit||S protein +Adjuvant||National Institute of Infectious Disease, Japan/Shionogi/UMN Pharma||SARS-CoV2||Pre-Clinical||Influenza|
|Protein Subunit||VLP-recombinant protein + Adjuvant||
Osaka University/ BIKEN/ National Institutes of Biomedical Innovation,
|Protein Subunit||microneedle arrays S1 subunit||Univ. of Pittsburgh||SARS-CoV2||Pre-Clinical||MERS|
|Protein Subunit||Peptide||Vaxil Bio||SARS-CoV2||Pre-Clinical|
|Protein Subunit||Peptide||Flow Pharma Inc||SARS-CoV2||Pre-Clinical||
Ebola, Marburg, HIV, Zika, Influenza, HPV therapeutic vaccine, BreastCA
|Protein Subunit||S protein||AJ Vaccines||SARS-CoV2||Pre-Clinical|
|Protein Subunit||Ii-Key peptide||Generex/EpiVax||SARS-CoV2||Pre-Clinical||Influenza, HIV, SARS-CoV|
|Protein Subunit||S protein||EpiVax/Univ. of Georgia||SARS-CoV2||Pre-Clinical||H7N9|
|Protein Subunit||Protein Subunit EPV-CoV-19||EpiVax||SARS-CoV2||Pre-Clinical|
|Protein Subunit||gp-96 backbone||Heat Biologics/Univ. Of Miami||SARS-CoV2||Pre-Clinical||NSCLC, HIV, malaria, Zika|
|Protein Subunit||Subunit vaccine||FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo||SARS-CoV2||Pre-Clinical|
|Protein Subunit||S1 or RBD protein||Baylor College of Medicine||SARS-CoV2||Pre-Clinical||SARS|
|Protein Subunit||Subunit protein, plant produced||iBio/CC-Pharming||SARS-CoV2||Pre-Clinical|
Recombinant protein, nanoparticles (based
on S-protein and other epitopes)
|Saint-Petersburg scientific research institute of vaccines and serums||SARS-CoV2||Pre-Clinical|
truncated S (spike) proteins
|Protein Subunit||Adjuvanted microsphere peptide||VIDO-InterVac, University of Saskatchewan||SARS-CoV2||Pre-Clinical|
Synthetic Long Peptide Vaccine candidate for
S and M proteins
Oral E. coli-based protein expression system
of S and N proteins
|MIGAL Galilee Research Institute||SARS-CoV2||Pre-Clinical|
|Protein Subunit||Nanoparticle vaccine||LakePharma, Inc.||SARS-CoV2||Pre-Clinical|
(RBD-Fc + Adjuvant)
|Baiya Phytopharm/ Chula Vaccine Research Center||SARS-CoV2||Pre-Clinical|
|Protein Subunit||OMV-based vaccine||Quadram Institute Biosciences||SARS-CoV2||Pre-Clinical||Flu A, plague|
|Protein Subunit||OMV-based vaccine||BiOMViS Srl/Univ. of Trento||SARS-CoV2||Pre-Clinical|
structurally modified spherical particles of
the tobacco mosaic virus (TMV)
|Lomonosov Moscow State University||SARS-CoV2||Pre-Clinical||rubella, rotavirus|
|Protein Subunit||Spike-based||University of Alberta||SARS-CoV2||Pre-Clinical||Hepatitis C|
|Protein Subunit||Recombinant S1-Fc fusion protein||AnyGo Technology||SARS-CoV2||Pre-Clinical|
|Protein Subunit||Recombinant protein||Yisheng Biopharma||SARS-CoV2||Pre-Clinical|
|Protein Subunit||Recombinant S protein in IC-BEVS||Vabiotech||SARS-CoV2||Pre-Clinical|
|Protein Subunit||Orally delivered, heat stable subunit||Applied Biotechnology Institute, Inc.||SARS-CoV2||Pre-Clinical|
|Protein Subunit||Peptides derived from Spike protein||Axon Neuroscience SE||SARS-CoV2||Pre-Clinical|
|Protein Subunit||Protein Subunit||MOGAM Institute for Biomedical Research, GC Pharma||SARS-CoV2||Pre-Clinical|
|Protein Subunit||RBD-based||Neovii/Tel Aviv University||SARS-CoV2||Pre-Clinical|
|Protein Subunit||Outer Membrane Vesicle (OMV)-subunit||Intravacc/Epivax||SARS-CoV2||Pre-Clinical|
|Protein Subunit||Outer Membrane Vesicle(OMV)-peptide||Intravacc/Epivax||SARS-CoV2||Pre-Clinical|
|Protein Subunit||Spike-based (epitope screening)||ImmunoPrecise/LiteVax BV||SARS-CoV2||Pre-Clinical|
Nanografi Nano Technology, Middle East Technical University, Ankara
|Replicating Bacteria Vector||
Oral Salmonella enteritidis (3934Vac) based
protein expression system of RBD
Farmacológicos Veterinarios SAC (FARVET SAC) / Universidad Peruana
Cayetano Heredia (UPCH)
|Replicating Viral Vector||
Intranasal Newcastle disease virus vector
(rNDV-FARVET) expressing RBD
Farmacológicos Veterinarios SAC (FARVET SAC) / Universidad Peruana
Cayetano Heredia (UPCH)
|Replicating Viral Vector||YF17D Vector||KU Leuven||SARS-CoV2||Pre-Clinical|
|Replicating Viral Vector||Measles Vector||Cadila Healthcare Limited||SARS-CoV2||Pre-Clinical|
|Replicating Viral Vector||Measles Vector||FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo||SARS-CoV2||Pre-Clinical|
|Replicating Viral Vector||Measles Virus (S, N targets)||DZIF – German Center for Infection Research/CanVirex AG||SARS-CoV2||Pre-clinical||Zika, H7N9, CHIKV|
|Replicating Viral Vector||Horsepox vector expressing S protein||Tonix Pharma/Southern Research||SARS-CoV2||Pre-Clinical||Smallpox, monkeypox|
|Replicating Viral Vector||Live viral vectored vaccine based on attenuated influenza virus backbone (intranasal)||BiOCAD and IEM||SARS-CoV2||Pre-Clinical||Influenza|
|Replicating Viral Vector||Recombinant vaccine based on Influenza A virus, for the prevention of COVID-19 (intranasal)||FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo||SARS-CoV2||Pre-Clinical||Influenza|
|Replicating Viral Vector||
Attenuated Influenza expressing
an antigenic portion of the Spike protein
|Fundação Oswaldo Cruz and Instituto Buntantan||SARS-CoV2||Pre-Clinical||Influenza|
|Replicating Viral Vector||Influenza vector expressing RBD||University of Hong Kong||SARS-CoV2||Pre-Clinical|
|Replicating Viral Vector||Replicating VSV vector-based DC-targeting||University of Manitoba||SARS-CoV2||Pre-Clinical|
|Replicating Viral Vector||VSV-S||University of Western Ontario||SARS-CoV2||Pre-Clinical||HIV, MERS|
|Replicating Viral Vector||VSV-S||Aurobindo||SARS-CoV2||Pre-Clinical|
|Replicating Viral Vector||VSV vector||FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo||SARS-CoV2||Pre-Clinical|
|Replicating Viral Vector||
M2-deficient single replication (M2SR)
|Replicating Viral Vector||
Newcastle disease virus vector (NDV-SARS-
|Intravacc/ Wageningen Bioveterinary Research/Utrecht Univ.||SARS-CoV2||Pre-Clinical|
|Replicating Viral Vector||Avian paramyxovirus vector (APMV)||The Lancaster University, UK||SARS-CoV2||Pre-Clinical|
|RNA||mRNA||Cell Tech Pharmed||SARS-CoV2||Pre-Clinical|
|RNA||D614G variant LNP-encapsulated mRNA||Globe Biotech Ltd||SARS-CoV2||Pre-Clinical|
|RNA||saRNA formulated in a NLC||Infectious Disease Research Institute/ Amyris, Inc.||SARS-CoV2||Pre-Clinical|
|RNA||LNP-encapsulated mRNA encoding S||Max-Planck-Institute of Colloids and Interfaces||SARS-CoV2||Pre-Clinical|
|RNA||LNP-mRNA||Translate Bio/Sanofi Pasteur||SARS-CoV2||Pre-Clinical|
|RNA||LNP-mRNA||CanSino Biologics/Precision NanoSystems||SARS-CoV2||Pre-Clinical|
LNP-encapsulated mRNA cocktail encoding
|Fudan University/ Shanghai JiaoTong University/RNACure Biopharma||SARS-CoV2||Pre-Clinical|
|RNA||LNP-encapsulated mRNA encoding RBD||Fudan University/ Shanghai JiaoTong University/RNACure Biopharma||SARS-CoV2||Pre-Clinical|
Replicating Defective SARS-CoV-2 derived
|Centro Nacional Biotecnología (CNB-CSIC), Spain||SARS-CoV2||Pre-Clinical|
|RNA||LNP-encapsulated mRNA||University of Tokyo/ Daiichi-Sankyo||SARS-CoV2||Pre-Clinical||MERS|
|RNA||Several mRNA candidates||RNAimmune, Inc.||SARS-CoV2||Pre-Clinical|
|RNA||mRNA||FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo||SARS-CoV2||Pre-Clinical|
|RNA||mRNA||China CDC/Tongji University/Stermina||SARS-CoV2||Pre-Clinical|
|RNA||LNP-mRNA||Chula Vaccine Research Center/University of Pennsylvania||SARS-CoV2||Pre-Clinical|
|RNA||mRNA in an intranasal delivery system||eTheRNA||SARS-CoV2||Pre-Clinical|
|RNA||mRNA||IDIBAPS-Hospital Clinic, Spain||SARS-CoV2||Pre-Clinical|
CD8 T cell peptide targeting (S, M, N) and
(NSPs) SARS-CoV-2 proteins
|VLP||Plant derived VLP||Shiraz University||SARS-CoV2||Pre-Clinical|
|VLP||VLPs produced in BEVS||Tampere University||SARS-CoV2||Pre-Clinical|
|VLP||VLP||Max Planck Institute for Dynamics of Complex Technical Systems||SARS-CoV2||Pre-Clinical|
Virus-like particle-based Dendritic Cell(DC)-
|University of Manitoba||SARS-CoV2||Pre-Clinical|
|VLP||VLP||Bezmialem Vakif University||SARS-CoV2||Pre-Clinical|
|VLP||VLP||Middle East Technical University||SARS-CoV2||Pre-Clinical|
|VLP||Enveloped Virus-Like Particle (eVLP)||VBI Vaccines Inc.||
|Pre-Clinical||CMV, GBM, Zika|
|VLP||S protein integrated in HIV VLPs||
IrsiCaixa AIDS Research/IRTA-CReSA/Barcelona Supercomputing
|VLP||VLP + Adjuvant||
Mahidol University/ The Government Pharmaceutical Organization
Virus-like particles, lentivirus and
|Navarrabiomed, Oncoimmunology group||SARS-CoV2||Pre-Clinical|
Virus-like particle, based on RBD displayed
on virus-like particles
|VLP||ADDomerTM multiepitope display||Imophoron Ltd and Bristol University’s Max Planck Centre||SARS-CoV2||Pre-Clinical|
|VLP||VLPs peptides/whole virus||Univ. of Sao Paulo||SARS-CoV2||Pre-Clinical|
6. Tumor/Cancer vaccines
GeneMedi’s Promise-ORFTM offers the larger collection of ORF/cDNA expression clones of human, mouse, rat and some other species. All ORFs expression clones in viral vectors (lentivirus, AAV and adenovirus) or mammalian expression vectors are sequences-verified. Using our Promise-ORFTM viral-ready expression vectors, you can easily promote your viral vectors packaging, or you can transfect your mammalian cells directly with stronger expression and easier detection.
Despite several decades’ continuous efforts on tumor therapy with radiation treatment and chemotherapy, serious adverse effects, including nausea, vomiting, physical weakness, mental malaise, sweating, decreased white blood cells and platelets, are really painful and intolerable. Tumor vaccines are vaccines using tumor-specific antigens (TSAs) to provoke the host immune system to specifically eliminate and suppress tumors or cancers, exhibiting promising advantages over traditional radiation and chemotherapy. Several kinds of tumor vaccines are developed for the therapy of tumor as shown in Fig. 18 , including nucleic acid vaccines (DNA vaccines and RNA vaccines), protein/peptide vaccines, and cell-based vaccines with tumor antigens.
Nucleic acid-based vaccines can be taken up by APCs and translated into specific antigen to provoke host immune system, such as Tyrosinase Related Protein 1 (TYRP1/gp75) vaccine for the treatment of melanoma . Protein/peptide-based vaccines are tumor specific antigens protein or epitope, which can directly stimulate immune system, such as HSPPC-96 vaccine (Oncophage) for the treatment of melanoma, gastric cancer, renal cell cancer, lymphoma, and pancreatic cancer . Cell-based vaccines are autologous dendritic cells or other immune cells with insertion of tumor antigen genes or transfected with tumor antigens or peptides, such as dendritic cell vaccine, provenge (sipuleucel-T), targeting PAP for the therapy of prostate cancer . A large number of tumor vaccines have been translated into clinics and encouraging therapy outcomes have been achieved (Table 12).
|Prostate cancer||PAP||DNA vaccine||Intravenous||Phase III||Improved survival|||
|Prostate cancer||VEGF Receptor 2||DNA vaccine||Oral||Phase I||Vaccine were well-tolerated and T effector was increased|||
|NSCLC||MUC1||Protein/peptide-based vaccines||Intravenous||Phase III||Tecemotide might have some adverse events on patients who initially receive concurrent chemoradiotherapy|||
|NSCLC||MUC1||Protein/peptide-based vaccines||Subcutaneous||Phase III||Safe, but adverse events existed|||
|Melanoma||HSPPC-96||Protein/peptide-based vaccines||Intradermal||Phase I/II||Feasible and safe. Modest immune response and anti-tumor activity were observed|||
|Ovarian carcinoma, glioblastoma, pancreatic carcinoma, stomach carcinoma||Multiple tumor-associated antigens (TAAs)||Tumor cell vaccine||Intradermal||Phase I/II||Antitumor immune memory and patient survival were improved|||
|Prostate cancer||PAP||Recombinant adenoviral vector-based vaccine||Subcutaneous||Phase I/II||Safe with no serious vaccine-related adverse events, and anti-PSA T-cell responses were induced|||
|Melanoma||IL-2||Autologous tumor cell vaccine via Ad vector-mediated IL-2 transfection||Intradermal/subcutaneous||Phase I||Safe and tolerate|||
|Melanoma||MART-1 or gp100||Recombinant adenoviral vector-based vaccine||Intramuscular/subcutaneous||Phase I||Safe, but presenting high levels of neutralizing antibody.|||
|Melanoma||GM-CSF||Irradiated autologous tumor cell vaccine via Ad vector-mediated GM-CSF transfection||Intradermal/subcutaneous||Phase I||Well tolerated and induce anti-tumor immune response|||
|Melanoma||MART-1||Autologous dendritic cell vaccine via Ad vector-mediated MART-1 transfection||Intradermal||Phase I/II||Safe and immunogenic|||
|Solid tumor||HER2||DNA vaccine and adenoviral vector-based vaccine||Intramuscular||Phase I||Well tolerated and without any serious adverse events|||
|Non-muscle-invasive bladder cancer (NMIBC)||IFNα/Syn3||Recombinant adenoviral vector-based vaccine||Intravesical||Phase II||Well tolerated|||
|Non-muscle-invasive bladder cancer (NMIBC)||IFNα2b/Syn4||Recombinant adenoviral vector-based vaccine||Intravesical||Phase Ib||Promising drug efficacy was shown|||
|Non-muscle-invasive bladder cancer (NMIBC)||IFNα/Syn3||Recombinant adenoviral vector-based vaccine||Intravesical||Phase I||Well tolerated with no dose limiting toxicity|||
|Colorectal cancer||CEA||Recombinant adenoviral vector-based vaccine||Subcutaneous||Phase I/II||Safe and immunogenic|||
|Colorectal cancer||CEA||Recombinant adenoviral vector-based vaccine||Subcutaneous||Phase I||Minimal toxicity|||
|Hepatocellular cancer||AFP||DNA vaccine and adenoviral vector-based vaccine||Intramuscular||Phase I||Safe and immunogenic|||
|B-cell lymphosarcoma||Telomerase||Recombinant adenoviral vector-based vaccine||In femoral biceps||Phase I||Safe and prolong the survival time|||
As is known to all, there are many somatic mutations in tumors varying in different individuals, and more and more highly heterogeneous neoantigens are discovered and identified through next generation sequencing (NGS) technologies. On the basis of tumor mutation profiles, personalized cancer vaccines are designed and developed to activate immune system against cancer by targeting specific epitopes of neoantigens (Fig. 19). Once delivered into the body with adjuvant, personal vaccines provokes host immune responses through the following processes:
① Neoantigen-specific peptides inside personal vaccines are captured and processed by APCs;
② Activated APCs migrate to lymph nodes and present neoantigens to T cells with MHC molecules;
③ Neoantigens are recognized and bound by T cell receptor, thus priming and activating cell immunity;
④ Neoantigen-specific T cells are expanded, migrate and infiltrate to tumor microenvironment;
⑤ Neoantigen-specific T cells kill tumor cells with neoantigens, leading to the release of more antigens, which elicits adaptive immune memory and augments the immune responses.
So far, personal vaccines have achieved encouraging anti-tumor effects in the pre-clinical studies with mouse models and clinical trials. For example, using whole-exome and transcriptome sequencing and mass spectrometry analysis, more than 1300 amino acid changes were identified in MC-38 and TRAMP-C1 murine tumor models, and vaccination with mutated peptides exhibits remarkable and sustainable inhibition of tumor growth . For human melanoma therapy, a neoantigen was discovered via whole exome sequencing and HLA binding prediction algorithm, and dendritic cell vaccine with the neoantigen significantly enhances the T cell immune response to the neoantigen in some patients .
Figure 19. Schematic of strategies and principles of personal neoantigen vaccines . (I) Get the tumor specimen from patient and extract the DNA. (II) Characterize the non-synonymous mutations via NGS. (III) Prepare the personal neoantigen vaccine in vitro and deliver the vaccine to patients with adjuvant.
In summary, different kinds of vaccines have their specific advantages and disadvantages (Table 13), and people should select the most suitable vaccines according to their demands. Although nucleic acid-based vaccines need short-term and little cost, DNA-based vaccines provoke mild immune responses, and no available mRNA vaccines have been applied into clinics, which really restrict the application of nucleic acid-based vaccines. Viral vector-based vaccines, especially adenoviral vector-based vaccines, stimulate relatively stronger immune responses, showing unique superiority in vaccine development. However, the COVID-19 is raging across the world now, which makes the vaccines for COVID-19 urgently demanded. At this fierce moment, time is really precious for life, which might give a chance for mRNA vaccine. At the same time, as a kind of effective and efficacious vaccines, viral vector-based vaccines are also promising and with great prospect for COVID-19 vaccine development.
|Viral vector-based vaccines||DNA vaccine||RNA vaccine|
|Immune responses||Induce humoral and cellular immunity||Induce humoral and cellular immunity||Induce humoral and cellular immunity|
|Immunogenicity||Varies with different vectors||Weak||Weak|
①highly efficient in gene transduction;
② mediate specific gene delivery to target cells;
③induce of both humoral and cell-mediated immune responses;
④ better efficacy and safety;
⑤ just need low administration dose;
⑥ easy to be applied into large-scale manufacturing;
⑦ possessing widespread potential target diseases, ranging from infectious diseases to cancers
|① Induction of humoral immune responses and cell immune responses;
② Avoid the anti-vector immunity;
③ Easy to produce in a large scale
|① Induction of humoral immune responses and cell immune responses; |
② Provoke stronger immunity than DNA vaccines;
③ Avoid the anti-vector immunity;
④ Mediate transient expression of antigen;
⑤ No integration into host genome;
⑥ Easy to produce in a large scale
Pre-existing immunity and neutralizing antibodies (AAV and AdV); tumorigenicity (LV)
|Induce weak immunity||Induce weak immunity|
|Suitable time||AAV and LV: long-term stable expression; |
|Delivery system||Viral vector||Naked nucleic acids, formulation with liposomes, lipoplexes, polyplexes, particulate carrier-mediated, electroporation, and gene gun|
Naked nucleic acids, formulation with liposomes, lipoplexes, polyplexes, particulate carrier-mediated, electroporation, and gene gun
|Optimization||AAV: rational design of capsid;
AdV: modify fiber protein to alter tissue tropism;
LV: develop integration-free vector
① Utilizing stronger promoters;
② Optimize the delivery route;
③ Optimization of multiple antigen sequences;
④ Adjuvants are used to prevent tolerance induction and facilitate the innate immune signals;
⑤ circumvent potential inhibitory effects of the vector
|① Modify or optimize the vaccine backbone;|
② Optimize the delivery systems and route of administration;
③ supplementation with small immunomodulatory molecules to improve the immune responses
|Clinical usage||Yes||Not yet||Not yet|
Ura T, Okuda K, Shimada M. Developments in Viral Vector-Based Vaccines. Vaccines (Basel). 2014;2:624-641.
2. Shirley JL, de Jong YP, Terhorst C, Herzog RW. Immune Responses to Viral Gene Therapy Vectors. Mol Ther. 2020;28:709-722.
3. Atchison RW, Casto BC, Hammon WM. Adenovirus-Associated Defective Virus Particles. Science. 1965;149:754-756.
4. Hoggan MD, Blacklow NR, Rowe WP. Studies of small DNA viruses found in various adenovirus preparations: physical, biological, and immunological characteristics. Proceedings of the National Academy of Sciences of the United States of
5. Bartlett JS, Wilcher R, Samulski RJ. Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors. Journal of virology. 2000;74:2777-2785.
6. Ding W, Zhang L, Yan Z, Engelhardt JF. Intracellular trafficking of adeno-associated viral vectors. Gene therapy. 2005;12:873-880.
7. Srivastava A. Adeno-associated virus-mediated gene transfer. Journal of cellular biochemistry. 2008;105:17-24.
8. Berns KI. Parvovirus replication. Microbiological reviews. 1990;54:316-329.
9. Pereira DJ, McCarty DM, Muzyczka N. The adeno-associated virus (AAV) Rep protein acts as both a repressor and an activator to regulate AAV transcription during a productive infection. Journal of virology. 1997;71:1079-1088.
10. Zhu J, Huang X, Yang Y. The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice. J Clin Invest. 2009;119:2388-2398.
11. Hosel M, Broxtermann M, Janicki H, Esser K, Arzberger S, Hartmann P, et al. Toll-like receptor 2-mediated innate immune response in human nonparenchymal liver cells toward adeno-associated viral vectors. Hepatology. 2012;55:287-297.
12. Pien GC, Basner-Tschakarjan E, Hui DJ, Mentlik AN, Finn JD, Hasbrouck NC, et al. Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors. J Clin Invest. 2009;119:1688-1
13. Shirley JL, Keeler GD, Sherman A, Zolotukhin I, Markusic DM, Hoffman BE, et al. Type I IFN Sensing by cDCs and CD4(+) T Cell Help Are Both Requisite for Cross-Priming of AAV Capsid-Specific CD8(+) T Cells. Mol Ther. 2020;28:758-770.
14. Sudres M, Cire S, Vasseur V, Brault L, Da Rocha S, Boisgerault F, et al. MyD88 signaling in B cells regulates the production of Th1-dependent antibodies to AAV. Mol Ther. 2012;20:1571-1581.
15. Rabinowitz J, Chan YK, Samulski RJ. Adeno-associated Virus (AAV) versus Immune Response. Viruses. 2019;11.
16. Weitzman MD, Linden RM. Adeno-associated virus biology. Methods in molecular biology. 2011;807:1-23.
17. Vectors used in gene therapy clinical trials. The Journal of Gene Medicine Online Library. [Online] Updated Nov 2017.
18. Kassner U, Hollstein T, Grenkowitz T, Wuhle-Demuth M, Salewsky B, Demuth I, et al. Gene Therapy in Lipoprotein Lipase Deficiency: Case Report on the First Patient Treated with Alipogene Tiparvovec Under Daily Practice Conditions. Hum
19. Passini MA, Bu J, Richards AM, Treleaven CM, Sullivan JA, O'Riordan CR, et al. Translational fidelity of intrathecal delivery of self-complementary AAV9-survival motor neuron 1 for spinal muscular atrophy. Human gene therapy. 2014;25
20. Stieger K, Lorenz B. [Specific gene therapy for hereditary retinal dystrophies - an update]. Klinische Monatsblatter fur Augenheilkunde. 2014;231:210-215.
21. Trapani I, Colella P, Sommella A, Iodice C, Cesi G, de Simone S, et al. Effective delivery of large genes to the retina by dual AAV vectors. EMBO molecular medicine. 2014;6:194-211.
22. Doi K, Takeuchi Y. Gene therapy using retrovirus vectors: vector development and biosafety at clinical trials. Uirusu. 2015;65:27-36.
23. Duncan GA, Kim N, Colon-Cortes Y, Rodriguez J, Mazur M, Birket SE, et al. An Adeno-Associated Viral Vector Capable of Penetrating the Mucus Barrier to Inhaled Gene Therapy. Molecular therapy. Methods & clinical development. 2018;9:29
24. Bowles DE, McPhee SW, Li C, Gray SJ, Samulski JJ, Camp AS, et al. Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Molecular therapy : the journal of the American Society of Gene Therap
25. Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. The New England journal of medicine. 2011;365:2357-2365.
26. Jessup M, Greenberg B, Mancini D, Cappola T, Pauly DF, Jaski B, et al. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reti
27. LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN, et al. AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. The Lancet. Neurology. 2011;10:309-319.
28. Aalbers CJ, Bevaart L, Loiler S, de Cortie K, Wright JF, Mingozzi F, et al. Preclinical Potency and Biodistribution Studies of an AAV 5 Vector Expressing Human Interferon-beta (ART-I02) for Local Treatment of Patients with Rheumatoid
29. Bevaart L, Aalbers CJ, Vierboom MP, Broekstra N, Kondova I, Breedveld E, et al. Safety, Biodistribution, and Efficacy of an AAV-5 Vector Encoding Human Interferon-Beta (ART-I02) Delivered via Intra-Articular Injection in Rhesus Monke
30. Xin KQ, Urabe M, Yang J, Nomiyama K, Mizukami H, Hamajima K, et al. A novel recombinant adeno-associated virus vaccine induces a long-term humoral immune response to human immunodeficiency virus. Hum Gene Ther. 2001;12:1047-1061.
31. Xin KQ, Ooki T, Mizukami H, Hamajima K, Okudela K, Hashimoto K, et al. Oral administration of recombinant adeno-associated virus elicits human immunodeficiency virus-specific immune responses. Hum Gene Ther. 2002;13:1571-1581.
32. Xin KQ, Mizukami H, Urabe M, Toda Y, Shinoda K, Yoshida A, et al. Induction of robust immune responses against human immunodeficiency virus is supported by the inherent tropism of adeno-associated virus type 5 for dendritic cells. J
33. Lin J, Calcedo R, Vandenberghe LH, Bell P, Somanathan S, Wilson JM. A new genetic vaccine platform based on an adeno-associated virus isolated from a rhesus macaque. J Virol. 2009;83:12738-12750.
34. Nieto K, Stahl-Hennig C, Leuchs B, Muller M, Gissmann L, Kleinschmidt JA. Intranasal vaccination with AAV5 and 9 vectors against human papillomavirus type 16 in rhesus macaques. Hum Gene Ther. 2012;23:733-741.
35. Grieger JC, Samulski RJ. Packaging capacity of adeno-associated virus serotypes: impact of larger genomes on infectivity and postentry steps. Journal of virology. 2005;79:9933-9944.
36. Fitzpatrick Z, Leborgne C, Barbon E, Masat E, Ronzitti G, van Wittenberghe L, et al. Influence of Pre-existing Anti-capsid Neutralizing and Binding Antibodies on AAV Vector Transduction. Mol Ther Methods Clin Dev. 2018;9:119-129.
37. Kotterman MA, Schaffer DV. Engineering adeno-associated viruses for clinical gene therapy. Nat Rev Genet. 2014;15:445-451.
38. Grimm D, Zolotukhin S. E Pluribus Unum: 50 Years of Research, Millions of Viruses, and One Goal--Tailored Acceleration of AAV Evolution. Mol Ther. 2015;23:1819-1831.
39. Maheshri N, Koerber JT, Kaspar BK, Schaffer DV. Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nature biotechnology. 2006;24:198-204.
40. Khabou H, Desrosiers M, Winckler C, Fouquet S, Auregan G, Bemelmans AP, et al. Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnology and bioengineering. 2016;113:2712-2
41. Kienle E, Senis E, Borner K, Niopek D, Wiedtke E, Grosse S, et al. Engineering and evolution of synthetic adeno-associated virus (AAV) gene therapy vectors via DNA family shuffling. Journal of visualized experiments : JoVE. 2012.
42. Rowe WP, Huebner RJ, Gilmore LK, Parrott RH, Ward TG. Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture. Proceedings of the Society for Experimental Biology and Medicine. So
43. Wong CM, McFall ER, Burns JK, Parks RJ. The role of chromatin in adenoviral vector function. Viruses. 2013;5:1500-1515.
44. Ranki T, Hemminki A. Serotype chimeric human adenoviruses for cancer gene therapy. Viruses. 2010;2:2196-2212.
45. Ison MG, Hayden RT. Adenovirus. Microbiology spectrum. 2016;4.
46. Vorburger SA, Hunt KK. Adenoviral gene therapy. The oncologist. 2002;7:46-59.
47. Seiler MP, Cerullo V, Lee B. Immune response to helper dependent adenoviral mediated liver gene therapy: challenges and prospects. Curr Gene Ther. 2007;7:297-305.
48. Othman M, Labelle A, Mazzetti I, Elbatarny HS, Lillicrap D. Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance. Blood. 2007;109:2832-2839.
49. Atasheva S, Shayakhmetov DM. Adenovirus sensing by the immune system. Curr Opin Virol. 2016;21:109-113.
50. Doronin K, Flatt JW, Di Paolo NC, Khare R, Kalyuzhniy O, Acchione M, et al. Coagulation factor X activates innate immunity to human species C adenovirus. Science. 2012;338:795-798.
51. Tam JC, Bidgood SR, McEwan WA, James LC. Intracellular sensing of complement C3 activates cell autonomous immunity. Science. 2014;345:1256070.
52. Parker AL, Waddington SN, Nicol CG, Shayakhmetov DM, Buckley SM, Denby L, et al. Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood. 2006;108:2554-2561.
53. Shayakhmetov DM, Gaggar A, Ni S, Li ZY, Lieber A. Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J Virol. 2005;79:7478-7491.
54. Allen RJ, Byrnes AP. Interaction of adenovirus with antibodies, complement, and coagulation factors. FEBS Lett. 2019;593:3449-3460.
55. Cotter MJ, Zaiss AK, Muruve DA. Neutrophils interact with adenovirus vectors via Fc receptors and complement receptor 1. J Virol. 2005;79:14622-14631.
56. McEwan WA, Tam JC, Watkinson RE, Bidgood SR, Mallery DL, James LC. Intracellular antibody-bound pathogens stimulate immune signaling via the Fc receptor TRIM21. Nat Immunol. 2013;14:327-336.
57. Fletcher AJ, James LC. Coordinated Neutralization and Immune Activation by the Cytosolic Antibody Receptor TRIM21. J Virol. 2016;90:4856-4859.
58. Khare R, Hillestad ML, Xu Z, Byrnes AP, Barry MA. Circulating antibodies and macrophages as modulators of adenovirus pharmacology. J Virol. 2013;87:3678-3686.
59. Bottermann M, Foss S, van Tienen LM, Vaysburd M, Cruickshank J, O'Connell K, et al. TRIM21 mediates antibody inhibition of adenovirus-based gene delivery and vaccination. Proc Natl Acad Sci U S A. 2018;115:10440-10445.
60. Di Paolo NC, Baldwin LK, Irons EE, Papayannopoulou T, Tomlinson S, Shayakhmetov DM. IL-1alpha and complement cooperate in triggering local neutrophilic inflammation in response to adenovirus and eliminating virus-containing cells. PL
61. Di Paolo NC, Miao EA, Iwakura Y, Murali-Krishna K, Aderem A, Flavell RA, et al. Virus binding to a plasma membrane receptor triggers interleukin-1 alpha-mediated proinflammatory macrophage response in vivo. Immunity. 2009;31:110-121.
62. Muruve DA, Petrilli V, Zaiss AK, White LR, Clark SA, Ross PJ, et al. The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature. 2008;452:103-107.
63. Suzuki M, Bertin TK, Rogers GL, Cela RG, Zolotukhin I, Palmer DJ, et al. Differential type I interferon-dependent transgene silencing of helper-dependent adenoviral vs. adeno-associated viral vectors in vivo. Mol Ther. 2013;21:796-80
64. Anghelina D, Lam E, Falck-Pedersen E. Diminished Innate Antiviral Response to Adenovirus Vectors in cGAS/STING-Deficient Mice Minimally Impacts Adaptive Immunity. J Virol. 2016;90:5915-5927.
65. Wang L, Wen M, Cao X. Nuclear hnRNPA2B1 initiates and amplifies the innate immune response to DNA viruses. Science. 2019;365.
66. Avgousti DC, Herrmann C, Kulej K, Pancholi NJ, Sekulic N, Petrescu J, et al. A core viral protein binds host nucleosomes to sequester immune danger signals. Nature. 2016;535:173-177.
67. Fields PA, Kowalczyk DW, Arruda VR, Armstrong E, McCleland ML, Hagstrom JN, et al. Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX. Mol Ther. 2000;1:225-235.
68. Amalfitano A, Parks RJ. Separating fact from fiction: assessing the potential of modified adenovirus vectors for use in human gene therapy. Current gene therapy. 2002;2:111-133.
69. Appaiahgari MB, Vrati S. Adenoviruses as gene/vaccine delivery vectors: promises and pitfalls. Expert Opin Biol Ther. 2015;15:337-351.
70. Sweeney K, Hallden G. Oncolytic adenovirus-mediated therapy for prostate cancer. Oncolytic virotherapy. 2016;5:45-57.
71. Castro JE, Melo-Cardenas J, Urquiza M, Barajas-Gamboa JS, Pakbaz RS, Kipps TJ. Gene immunotherapy of chronic lymphocytic leukemia: a phase I study of intranodally injected adenovirus expressing a chimeric CD154 molecule. Cancer resea
72. Predina JD, Keating J, Venegas O, Nims S, Singhal S. Neoadjuvant intratumoral immuno-gene therapy for non-small cell lung cancer. Discovery medicine. 2016;21:275-281.
73. Schiza A, Wenthe J, Mangsbo S, Eriksson E, Nilsson A, Totterman TH, et al. Adenovirus-mediated CD40L gene transfer increases Teffector/Tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients. Journal of
74. Garcia-Carbonero R, Salazar R, Duran I, Osman-Garcia I, Paz-Ares L, Bozada JM, et al. Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection. Journal for i
75. Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Grove D, et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med. 2013;369:2083-2092.
76. Kibuuka H, Kimutai R, Maboko L, Sawe F, Schunk MS, Kroidl A, et al. A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172). J Infect Dis.
77. Gurwith M, Lock M, Taylor EM, Ishioka G, Alexander J, Mayall T, et al. Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1
78. Smaill F, Jeyanathan M, Smieja M, Medina MF, Thanthrige-Don N, Zganiacz A, et al. A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity. Sci Transl
79. Diaz CM, Chiappori A, Aurisicchio L, Bagchi A, Clark J, Dubey S, et al. Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors.
80. Kallel H, Kamen AA. Large-scale adenovirus and poxvirus-vectored vaccine manufacturing to enable clinical trials. Biotechnol J. 2015;10:741-747.
81. Perreau M, Pantaleo G, Kremer EJ. Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells. J Exp Med. 2008;205:2717-2725.
82. Sekaly RP. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J Exp Med. 2008;205:7-12.
83. Fausther-Bovendo H, Kobinger GP. Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what's important? Hum Vaccin Immunother. 2014;10:2875-2884.
84. Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci U S A. 1994;91:4407-4411.
85. Xin KQ, Jounai N, Someya K, Honma K, Mizuguchi H, Naganawa S, et al. Prime-boost vaccination with plasmid DNA and a chimeric adenovirus type 5 vector with type 35 fiber induces protective immunity against HIV. Gene Ther. 2005;12:1769
86. Gao GP, Yang Y, Wilson JM. Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J Virol. 1996;70:8934-8943.
87. Okada N, Iiyama S, Okada Y, Mizuguchi H, Hayakawa T, Nakagawa S, et al. Immunological properties and vaccine efficacy of murine dendritic cells simultaneously expressing melanoma-associated antigen and interleukin-12. Cancer Gene The
88. Salgado CD, Kilby JM. Retroviruses and other latent viruses: the deadliest of pathogens are not necessarily the best candidates for bioterrorism. Journal of the South Carolina Medical Association. 2009;105:104-106.
89. Jacome A, Navarro S, Rio P, Yanez RM, Gonzalez-Murillo A, Lozano ML, et al. Lentiviral-mediated genetic correction of hematopoietic and mesenchymal progenitor cells from Fanconi anemia patients. Molecular therapy : the journal of the
90. Yasutsugu Suzuki and Youichi Suzuki (July 20th 2011). Gene Regulatable Lentiviral Vector System, Viral Gene Therapy Ke Xu, IntechOpen, DOI: 10.5772/18155.
91. Borsotti C, Borroni E, Follenzi A. Lentiviral vector interactions with the host cell. Curr Opin Virol. 2016;21:102-108.
92. Rossetti M, Gregori S, Hauben E, Brown BD, Sergi LS, Naldini L, et al. HIV-1-derived lentiviral vectors directly activate plasmacytoid dendritic cells, which in turn induce the maturation of myeloid dendritic cells. Hum Gene Ther. 20
93. Wang CX, Torbett BE. Role of the mammalian target of rapamycin pathway in lentiviral vector transduction of hematopoietic stem cells. Curr Opin Hematol. 2015;22:302-308.
94. Merlin S, Cannizzo ES, Borroni E, Bruscaggin V, Schinco P, Tulalamba W, et al. A Novel Platform for Immune Tolerance Induction in Hemophilia A Mice. Mol Ther. 2017;25:1815-1830.
95. Merlin S, Follenzi A. Transcriptional Targeting and MicroRNA Regulation of Lentiviral Vectors. Mol Ther Methods Clin Dev. 2019;12:223-232.
96. Milone MC, O'Doherty U. Clinical use of lentiviral vectors. Leukemia. 2018;32:1529-1541.
97. Cavazzana-Calvo M, Payen E, Negre O, Wang G, Hehir K, Fusil F, et al. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature. 2010;467:318-322.
98. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, Veres G, Schmidt M, Kutschera I, et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science. 2009;326:818-823.
99. Biffi A, Montini E, Lorioli L, Cesani M, Fumagalli F, Plati T, et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science. 2013;341:1233158.
100. Sessa M, Lorioli L, Fumagalli F, Acquati S, Redaelli D, Baldoli C, et al. Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1/2 trial. Lancet. 2016;388:476-487.
101. Aiuti A, Biasco L, Scaramuzza S, Ferrua F, Cicalese MP, Baricordi C, et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science. 2013;341:1233151.
102. Palmowski MJ, Lopes L, Ikeda Y, Salio M, Cerundolo V, Collins MK. Intravenous injection of a lentiviral vector encoding NY-ESO-1 induces an effective CTL response. J Immunol. 2004;172:1582-1587.
103. Lopes L, Dewannieux M, Gileadi U, Bailey R, Ikeda Y, Whittaker C, et al. Immunization with a lentivector that targets tumor antigen expression to dendritic cells induces potent CD8+ and CD4+ T-cell responses. J Virol. 2008;82:86-95.
104. Bobisse S, Rondina M, Merlo A, Tisato V, Mandruzzato S, Amendola M, et al. Reprogramming T lymphocytes for melanoma adoptive immunotherapy by T-cell receptor gene transfer with lentiviral vectors. Cancer Res. 2009;69:9385-9394.
105. Iglesias MC, Mollier K, Beignon AS, Souque P, Adotevi O, Lemonnier F, et al. Lentiviral vectors encoding HIV-1 polyepitopes induce broad CTL responses in vivo. Mol Ther. 2007;15:1203-1210.
106. Dai B, Yang L, Yang H, Hu B, Baltimore D, Wang P. HIV-1 Gag-specific immunity induced by a lentivector-based vaccine directed to dendritic cells. Proc Natl Acad Sci U S A. 2009;106:20382-20387.
107. Lemiale F, Asefa B, Ye D, Chen C, Korokhov N, Humeau L. An HIV-based lentiviral vector as HIV vaccine candidate: Immunogenic characterization. Vaccine. 2010;28:1952-1961.
108. Sinn PL, Hickey MA, Staber PD, Dylla DE, Jeffers SA, Davidson BL, et al. Lentivirus vectors pseudotyped with filoviral envelope glycoproteins transduce airway epithelia from the apical surface independently of folate receptor alpha. J Virol. 2003;77:5902-5910.
109. Pistello M, Bonci F, Zabogli E, Conti F, Freer G, Maggi F, et al. Env-expressing autologous T lymphocytes induce neutralizing antibody and afford marked protection against feline immunodeficiency virus. J Virol. 2010;84:3845-3856.
110. Chiuppesi F, Vannucci L, De Luca A, Lai M, Matteoli B, Freer G, et al. A lentiviral vector-based, herpes simplex virus 1 (HSV-1) glycoprotein B vaccine affords cross-protection against HSV-1 and HSV-2 genital infections. J Virol. 2012;86:6563-6574.
111. Norton TD, Zhen A, Tada T, Kim J, Kitchen S, Landau NR. Lentiviral Vector-Based Dendritic Cell Vaccine Suppresses HIV Replication in Humanized Mice. Mol Ther. 2019;27:960-973.
112. Wee EG, Ondondo B, Berglund P, Archer J, McMichael AJ, Baltimore D, et al. HIV-1 Conserved Mosaics Delivered by Regimens with Integration-Deficient DC-Targeting Lentiviral Vector Induce Robust T Cells. Mol Ther. 2017;25:494-503.
113. Pinschewer DD. Virally vectored vaccine delivery: medical needs, mechanisms, advantages and challenges. Swiss Med Wkly. 2017;147:w14465.
114. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, et al. Direct gene transfer into mouse muscle in vivo. Science. 1990;247:1465-1468.
115. Tagawa ST, Lee P, Snively J, Boswell W, Ounpraseuth S, Lee S, et al. Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma. Cancer. 2003;98:144-154.
116. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science. 1993;259:1745-1749.
117. Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, Robinson HL. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci U S A. 1993;90:11478-11482.
118. Suschak JJ, Williams JA, Schmaljohn CS. Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity. Hum Vaccin Immunother. 2017;13:2837-2848.
119. Hobernik D, Bros M. DNA Vaccines-How Far From Clinical Use? Int J Mol Sci. 2018;19.
120. Cui Z. DNA vaccine. Adv Genet. 2005;54:257-289.
121. Colluru VT, Johnson LE, Olson BM, McNeel DG. Preclinical and clinical development of DNA vaccines for prostate cancer. Urol Oncol. 2016;34:193-204.
122. Boyle JS, Silva A, Brady JL, Lew AM. DNA immunization: induction of higher avidity antibody and effect of route on T cell cytotoxicity. Proc Natl Acad Sci U S A. 1997;94:14626-14631.
123. Weber R, Bossart W, Cone R, Luethy R, Moelling K. Phase I clinical trial with HIV-1 gp160 plasmid vaccine in HIV-1-infected asymptomatic subjects. Eur J Clin Microbiol Infect Dis. 2001;20:800-803.
124. Fidler S, Stohr W, Pace M, Dorrell L, Lever A, Pett S, et al. Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial. Lancet. 2020;395:888-898.
125. Spearman P, Mulligan M, Anderson EJ, Shane AL, Stephens K, Gibson T, et al. A phase 1, randomized, controlled dose-escalation study of EP-1300 polyepitope DNA vaccine against Plasmodium falciparum malaria administered via electroporation. Vaccine. 2016;34:5571-5578.
126. Klencke B, Matijevic M, Urban RG, Lathey JL, Hedley ML, Berry M, et al. Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. Clin Cancer Res. 2002;8:1028-1037.
127. Timmerman JM, Singh G, Hermanson G, Hobart P, Czerwinski DK, Taidi B, et al. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res. 2002;62:5845-5852.
128. Norell H, Poschke I, Charo J, Wei WZ, Erskine C, Piechocki MP, et al. Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial. J Transl Med. 2010;8:53.
129. Staff C, Mozaffari F, Haller BK, Wahren B, Liljefors M. A Phase I safety study of plasmid DNA immunization targeting carcinoembryonic antigen in colorectal cancer patients. Vaccine. 2011;29:6817-6822.
130. Conry RM, Curiel DT, Strong TV, Moore SE, Allen KO, Barlow DL, et al. Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients. Clin Cancer Res. 2002;8:2782-2787.
131. Ginsberg BA, Gallardo HF, Rasalan TS, Adamow M, Mu Z, Tandon S, et al. Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection. Clin Cancer Res. 2010;16:4057-4065.
132. Yuan J, Ku GY, Gallardo HF, Orlandi F, Manukian G, Rasalan TS, et al. Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma. Cancer Immun. 2009;9:5.
133. Wolchok JD, Yuan J, Houghton AN, Gallardo HF, Rasalan TS, Wang J, et al. Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma. Mol Ther. 2007;15:2044-2050.
134. Triozzi PL, Aldrich W, Allen KO, Carlisle RR, LoBuglio AF, Conry RM. Phase I study of a plasmid DNA vaccine encoding MART-1 in patients with resected melanoma at risk for relapse. J Immunother. 2005;28:382-388.
135. Weber J, Boswell W, Smith J, Hersh E, Snively J, Diaz M, et al. Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma. J Immunother. 2008;31:215-223.
136. Dangoor A, Lorigan P, Keilholz U, Schadendorf D, Harris A, Ottensmeier C, et al. Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine. Cancer Immunol Immunother. 2010;59:863-873.
137. Cassaday RD, Sondel PM, King DM, Macklin MD, Gan J, Warner TF, et al. A phase I study of immunization using particle-mediated epidermal delivery of genes for gp100 and GM-CSF into uninvolved skin of melanoma patients. Clin Cancer Res. 2007;13:540-549.
138. Nabel GJ, Gordon D, Bishop DK, Nickoloff BJ, Yang ZY, Aruga A, et al. Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc Natl Acad Sci U S A. 1996;93:15388-15393.
139. Nemunaitis J, Meyers T, Senzer N, Cunningham C, West H, Vallieres E, et al. Phase I Trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancer. Mol Ther. 2006;13:1185-1191.
140. Hovav AH, Panas MW, Rahman S, Sircar P, Gillard G, Cayabyab MJ, et al. Duration of antigen expression in vivo following DNA immunization modifies the magnitude, contraction, and secondary responses of CD8+ T lymphocytes. J Immunol. 2007;179:6725-6733.
141. Pollard C, De Koker S, Saelens X, Vanham G, Grooten J. Challenges and advances towards the rational design of mRNA vaccines. Trends Mol Med. 2013;19:705-713.
142. Iavarone C, O'Hagan D T, Yu D, Delahaye NF, Ulmer JB. Mechanism of action of mRNA-based vaccines. Expert Rev Vaccines. 2017;16:871-881.
143. De Beuckelaer A, Grooten J, De Koker S. Type I Interferons Modulate CD8(+) T Cell Immunity to mRNA Vaccines. Trends Mol Med. 2017;23:216-226.
144. Cruz CC, Suthar MS, Montgomery SA, Shabman R, Simmons J, Johnston RE, et al. Modulation of type I IFN induction by a virulence determinant within the alphavirus nsP1 protein. Virology. 2010;399:1-10.
145. Maruggi G, Shaw CA, Otten GR, Mason PW, Beard CW. Engineered alphavirus replicon vaccines based on known attenuated viral mutants show limited effects on immunogenicity. Virology. 2013;447:254-264.
146. Kramps T, Elbers K. Introduction to RNA Vaccines. Methods Mol Biol. 2017;1499:1-11.
147. Bedoui S, Whitney PG, Waithman J, Eidsmo L, Wakim L, Caminschi I, et al. Cross-presentation of viral and self antigens by skin-derived CD103+ dendritic cells. Nat Immunol. 2009;10:488-495.
148. Scheel B, Aulwurm S, Probst J, Stitz L, Hoerr I, Rammensee HG, et al. Therapeutic anti-tumor immunity triggered by injections of immunostimulating single-stranded RNA. Eur J Immunol. 2006;36:2807-2816.
149. Seregin SS, Appledorn DM, McBride AJ, Schuldt NJ, Aldhamen YA, Voss T, et al. Transient pretreatment with glucocorticoid ablates innate toxicity of systemically delivered adenoviral vectors without reducing efficacy. Mol Ther. 2009;17:685-696.
150. Kranz LM, Diken M, Haas H, Kreiter S, Loquai C, Reuter KC, et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature. 2016;534:396-401.
151. Sebastian M, Papachristofilou A, Weiss C, Fruh M, Cathomas R, Hilbe W, et al. Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive(R)) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer. BMC Cancer. 2014;14:748.
152. Weide B, Pascolo S, Scheel B, Derhovanessian E, Pflugfelder A, Eigentler TK, et al. Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients. J Immunother. 2009;32:498-507.
153. Weide B, Carralot JP, Reese A, Scheel B, Eigentler TK, Hoerr I, et al. Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. J Immunother. 2008;31:180-188.
154. Rittig SM, Haentschel M, Weimer KJ, Heine A, Muller MR, Brugger W, et al. Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. Mol Ther. 2011;19:990-999.
155. Rittig SM, Haentschel M, Weimer KJ, Heine A, Muller MR, Brugger W, et al. Long-term survival correlates with immunological responses in renal cell carcinoma patients treated with mRNA-based immunotherapy. Oncoimmunology. 2016;5:e1108511.
156. Alberer M, Gnad-Vogt U, Hong HS, Mehr KT, Backert L, Finak G, et al. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Lancet. 2017;390:1511-1520.
157. Bahl K, Senn JJ, Yuzhakov O, Bulychev A, Brito LA, Hassett KJ, et al. Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses. Mol Ther. 2017;25:1316-1327.
158. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395:514-523.
159. Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, et al. Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany. N Engl J Med. 2020;382:970-971.
160. Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen L, et al. Presumed Asymptomatic Carrier Transmission of COVID-19. JAMA. 2020.
161. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020.
162. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020.
163. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367:1260-1263.
164. Pan RY, Chung WH, Chu MT, Chen SJ, Chen HC, Zheng L, et al. Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens. J Immunol Res. 2018;2018:4325874.
165. Ghanem G, Fabrice J. Tyrosinase related protein 1 (TYRP1/gp75) in human cutaneous melanoma. Mol Oncol. 2011;5:150-155.
166. di Pietro A, Tosti G, Ferrucci PF, Testori A. Oncophage: step to the future for vaccine therapy in melanoma. Expert Opin Biol Ther. 2008;8:1973-1984.
167. Cheever MA, Higano CS. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res. 2011;17:3520-3526.
168. Schmitz-Winnenthal FH, Hohmann N, Niethammer AG, Friedrich T, Lubenau H, Springer M, et al. Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial. Oncoimmunology. 2015;4:e1001217.
169. Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15:59-68.
170. Butts C, Murray RN, Smith CJ, Ellis PM, Jasas K, Maksymiuk A, et al. A multicenter open-label study to assess the safety of a new formulation of BLP25 liposome vaccine in patients with unresectable stage III non-small-cell lung cancer. Clin Lung Cancer. 2010;11:391-395.
171. Eton O, Ross MI, East MJ, Mansfield PF, Papadopoulos N, Ellerhorst JA, et al. Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma. J Transl Med. 2010;8:9.
172. Schirrmacher V. Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory. Cancer Immunol Immunother. 2005;54:587-598.
173. Schreiber S, Kampgen E, Wagner E, Pirkhammer D, Trcka J, Korschan H, et al. Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: outcome of a phase I study. Hum Gene Ther. 1999;10:983-993.
174. Rosenberg SA, Zhai Y, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, et al. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst. 1998;90:1894-1900.
175. Kusumoto M, Umeda S, Ikubo A, Aoki Y, Tawfik O, Oben R, et al. Phase 1 clinical trial of irradiated autologous melanoma cells adenovirally transduced with human GM-CSF gene. Cancer Immunol Immunother. 2001;50:373-381.
176. Butterfield LH, Comin-Anduix B, Vujanovic L, Lee Y, Dissette VB, Yang JQ, et al. Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma. J Immunother. 2008;31:294-309.
177. Shore ND, Boorjian SA, Canter DJ, Ogan K, Karsh LI, Downs TM, et al. Intravesical rAd-IFNalpha/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. J Clin Oncol. 2017;35:3410-3416.
178. Navai N, Benedict WF, Zhang G, Abraham A, Ainslie N, Shah JB, et al. Phase 1b Trial to Evaluate Tissue Response to a Second Dose of Intravesical Recombinant Adenoviral Interferon alpha2b Formulated in Syn3 for Failures of Bacillus Calmette-Guerin (BCG) Therapy in Nonmuscle Invasive Bladder Cancer. Ann Surg Oncol. 2016;23:4110-4114.
179. Dinney CP, Fisher MB, Navai N, O'Donnell MA, Cutler D, Abraham A, et al. Phase I trial of intravesical recombinant adenovirus mediated interferon-alpha2b formulated in Syn3 for Bacillus Calmette-Guerin failures in nonmuscle invasive bladder cancer. J Urol. 2013;190:850-856.
180. Morse MA, Chaudhry A, Gabitzsch ES, Hobeika AC, Osada T, Clay TM, et al. Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients. Cancer Immunol Immunother. 2013;62:1293-1301.
181. Butterfield LH, Economou JS, Gamblin TC, Geller DA. Alpha fetoprotein DNA prime and adenovirus boost immunization of two hepatocellular cancer patients. J Transl Med. 2014;12:86.
182. Gavazza A, Lubas G, Fridman A, Peruzzi D, Impellizeri JA, Luberto L, et al. Safety and efficacy of a genetic vaccine targeting telomerase plus chemotherapy for the therapy of canine B-cell lymphoma. Hum Gene Ther. 2013;24:728-738.
183. Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, Bumbaca S, et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature. 2014;515:572-576.
184. Carreno BM, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti AA, et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science. 2015;348:803-808.
Collection of COVID-19 landscape knowledge base
COVID-19 landscape Knowledge Base
An Insight of comparison between COVID-19 (2019-nCoV disease) and SARS in pathology and pathogenesis
Landscape Coronavirus Disease 2019 test (COVID-19 test) in vitro -- A comparison of PCR vs Immunoassay vs Crispr-Based test